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Abstract 
A large proportion of the protein coding sequences in any genome lack functional characterization. Knowledge about the 
function of these uncharacterized regions can provide important insights into biological processes. Traditional 
classifications and methods for predicting protein function are largely based on principles that apply to structured domains 
that are well folded. These approaches do not explicitly consider Intrinsically Disordered Regions (IDRs) and Intrinsically 
Disordered Proteins (IDPs), which are polypeptide segments that do not adopt a defined tertiary structure. IDRs and IDPs 
are ubiquitous in any organism, are prevalent in uncharacterized proteins, and are different from structured domains in many 
ways. Classification schemes of IDRs are needed to enhance the functional characterization of this important class of 
protein segments. This review provides an overview of classifications of IDRs and IDPs. We discuss approaches that are 
based on function, functional elements, structure, sequence, protein interactions, evolution, regulation, and biophysical 
properties. We conclude with a discussion of resources currently available for gaining insight into IDR function and 
speculate how the combination of classifications could achieve high quality function prediction for disordered regions in 
proteins. 
 
1. Introduction 
 
1.1. Uncharacterized protein segments are a source of functional novelty 
Over the last decade, we have observed a massive increase in the amount of information describing protein sequences from 
a variety of organisms.1,2 While this may reflect the diversity in the sequence space, and possibly also in the function space,3 
a large proportion of the sequences lacks any useful functional annotation.4,5 Often these sequences are annotated as putative 
or hypothetical proteins and for the majority their functions still remain unknown.6,7 Suggestions about potential protein 
function, primarily molecular function, often come from computational analysis of their sequences. For instance, homology 
detection allows for the transfer of information on well-characterized protein segments to those with similar sequences that 
lack annotation of molecular function.8-10 Other aspects of function, such as the biological processes proteins participate in, 
may come from genetic- and disease-association studies, expression and interaction network data, and comparative 
genomics approaches investigating genomic context.11-17 Characterization of unannotated and uncharacterized protein 
segments is expected to lead to the discovery of novel functions as well as provide important insights into existing 
biological processes. In addition, it is likely to shed new light on molecular mechanisms of diseases that are not yet fully 
understood. Thus, uncharacterized protein segments are likely to be a large source of functional novelty relevant for 
discovering new biology. 
 
1.2. Structure-function paradigm enhances function prediction 
Traditionally, protein function has been viewed as critically dependent on the well-defined and folded three-dimensional 
structure of the polypeptide chain. This classical structure-function paradigm (Figure 1; left panel) has mainly been based 
on concepts explaining the specificity of enzymes, and protein structure determination methods utilizing X-ray diffraction 
on protein crystals. The classical concept implies that protein sequence defines structure, which in turn determines function, 
i.e. function can be inferred from the sequence and its structure. Even when proteins sequences diverge during evolution, for 
example after gene duplication, the overall fold of their structures remains roughly the same. Therefore, structural similarity 
between proteins can reveal distant evolutionary relationships that are not easily detectable using sequence-based 
methods.18,19 Structural genomics efforts such as the Protein Structure Initiative (PSI) have been set up to enlarge the space 
of known protein folds and their function, thereby complementing sequence-based methods in an attempt to fill the gap of 
sequences for which there is no functional annotation.20,21 Specifically, phase two of the PSI aimed to structurally 
characterize proteins and protein domains of unknown function, often providing the first hypothesis about their function and 
serving as a starting point in their experimental characterization. 
 
1.3. Classification further facilitates function prediction 
Classification schemes provide a guideline for systematic function assignment to proteins. Generally, proteins are made up 
of a single or multiple domains that can have distinct molecular functions. These domains, which are referred as structured 
domains, often fold independently, make precise tertiary contacts and adopt a specific three-dimensional structure to carry 
out their function. The sequences that compose structured domains can be organized into families of homologous 
sequences, whose members are likely to share common evolutionary relationship and molecular function. The Pfam 
database classifies known protein sequences and contains almost 15,000 such families, for most of which there is some 
understanding about the function.22 Nevertheless, Pfam also contains more than 3,000 families annotated as domains of 
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unknown function, or DUFs.23 These families are largely made up of hypothetical proteins and await function annotation. 
Another powerful example of a protein classification scheme is the Structural Classification of Proteins (SCOP), which 
provides a means of grouping proteins with known structure together, based on their structural and evolutionary 
relationships.24,25 SCOP utilizes a hierarchical classification consisting of four levels, (i) family (ii) superfamily (ii) fold and 
(iv) class, with each level corresponding to different degrees of structural similarity and evolutionary relatedness between 
members. Using this scheme, function of newly solved structures or sequences can be inferred from their similarity with 
existing protein classes through structure or sequence comparisons, for instance as available via the SUPERFAMILY 
database.10 In this direction, another major initiative is Genome3D, which is a collaborative project to annotate genomic 
sequences with predicted 3D structures based on CATH26 (Class, Architecture, Topology, Homology) and SCOP24,25 
domains to infer protein function.27 
 
1.4. Intrinsically Disordered Regions and Proteins 
While many proteins need to adopt a well-defined structure to carry out their function, a large fraction of the proteome of 
any organism consists of protein segments that are not likely to form a defined three-dimensional structure, but are 
nevertheless functional.28-41 These polypeptide segments are referred to as intrinsically disordered regions (IDRs; Figure 1; 
right panel).42 Since IDRs generally lack bulky hydrophobic amino acids, they are unlikely to form the well-organized 
hydrophobic core that makes up a structured domain31,43 and hence they follow rules that are different from the classical 
structure-function view. In this framework, protein sequences in a genome can be viewed as modular because they are made 
up of combinations of structured and disordered regions (Figure 1; bottom panel). Proteins without IDRs are called 
structured proteins and proteins with entirely disordered sequences that do not adopt any tertiary structure are referred to as 
intrinsically disordered proteins (IDPs). The majority of eukaryotic proteins are made up of both structured and disordered 
regions and both are important for the repertoire of functions that a protein can have in a variety of cellular contexts.42 
Traditionally, IDRs were considered to be passive segments in protein sequences that ‘linked’ structured domains. 
However, it is now well established that IDRs actively participate in diverse functions mediated by proteins. For instance, 
disordered regions are frequently subjected to post-translational modifications (PTMs) that increase the functional states in 
which a protein can exist in the cell.44,45 In addition, they expose short linear peptide motifs of about 3-10 amino acids that 
permit interaction with structured domains in other proteins.46,47 These two features in isolation or in combination permit 
interaction and recruitment of diverse proteins in space and time, thereby facilitating regulation of virtually all cellular 
processes.46 The prevalence of IDRs in any genome (see for example the D2P2 database,48 Box 1) in combination with their 
unique characteristics means that these regions extend the classical view of the structure-function paradigm and hence that 
of protein function. Thus, functional regions in proteins can either be structured or disordered, and these need to be 
considered as two fundamental classes of functional building blocks of proteins.49 
 
1.5. The need for classification of Intrinsically Disordered Regions and Proteins 
IDRs and IDPs are prevalent in eukaryotic genomes. For instance, 44% of human protein-coding genes contain substantial 
disordered segments of >30 amino acids in length (Figure 2A).48 In the human genome, 6.4% of all protein-coding genes do 
not have any function annotation in their description in ENSEMBL1 (Figure 2B). Further investigation using the D2P2 
database of disorder in genomes48 revealed that most of these genes with no function annotation encode at least some 
disorder (Figure 2B) and that genes with no annotation contain proportionally more IDRs (Figure 2C). Given the absence 
of structural constraints, IDRs tend to evolve more rapidly than protein domains that adopt defined structures.50-55 As a 
result, identifying homologous regions is harder for IDRs and IDPs than it is for structured domains. This complicates the 
transfer of function information between homologs and the prediction of function of IDRs and IDPs. Furthermore, much of 
protein annotation is based on information on sequence families and structured domains. However, less than half of all 
residues in the human proteome fall within such domains (Figure 3). Not only do most residues of human proteins fall 
outside domains, a large fraction of these residues are also disordered (Figure 3A and 3B, right bars). Furthermore, 
although it is expected that SUPERFAMILY domains based on known protein structures have very little disorder (Figure 
3A, left bar), Pfam domains based on sequence clustering do not contain much more (Figure 3B, left bar). These 
observations suggest that there is a large pool of protein segments that are not considered by conventional protein 
annotation methods, because the sequences of disordered regions are difficult to align, or because the methods do not 
explicitly consider disordered and non-domain sequences. Taken together, these considerations raise the need to devise a 
classification scheme specifically for disordered regions in proteins that may enhance the function prediction and annotation 
for this important class of protein segments. 
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In this review, we synthesize and provide an overview of the various classifications of Intrinsically Disordered Regions and 
Proteins that have been put forward in the literature since the start of systematic studies into their function some 15 years 
ago. We discuss approaches based on function, functional elements, structure, sequence, protein interactions, evolution, 
regulation, and biophysical properties (Table 1). Finally, we discuss resources that are currently available to gain insight 
into IDR function, we suggest areas where increased efforts are likely to advance our understanding of the functions of 
protein disorder, and we speculate how combinations of multiple existing classifications could achieve high quality function 
prediction for IDRs, which ultimately leads to improved function coverage and a deeper understanding of protein function. 
 
2. Function 
Dunker and co-workers56 distinguished 28 separate functions for disordered regions, based on literature analysis of 150 
proteins containing disordered regions of 30 residues or longer. These functionalities can be summarized as molecular 
recognition, molecular assembly, protein modification, and entropic chains. Further development of this scheme resulted in 
one comprising six different function classes of disordered protein regions: entropic chains, display sites, chaperones, 
effectors, assemblers, and scavengers (Figure 4).33,57 In line with this classification, Gsponer and Babu classified IDR 
function into three broad functional categories: (i) facilitated regulation via diverse post-translational modifications, (ii) 
scaffolding and recruitment of different binding partners, and (iii) conformational variability and adaptability (Figure 5).38 
A single protein may consist of several disordered regions that belong to different function classes, which may be associated 
with a specific position in the sequence.58 The following section will address and exemplify the six functionalities of 
disordered regions.  
 
2.1. Entropic chains 
Entropic chains carry out functions that benefit directly from their conformational disorder, i.e. they function without ever 
becoming structured. Examples of entropic chains include flexible linkers, which allow movement of two domains relative 
to each other, and spacers that regulate the distances between domains. Evidence that flexibility is a functional characteristic 
that needs to be maintained came from studies on a family of flexible linkers in the 70 kDa subunit of replication protein A 
(RPA70), which display conserved dynamic behavior in the face of negligible sequence conservation.59 The microtubule-
associated protein 2 (MAP2) projection domain exemplifies spacer behavior as it repels molecules that approach 
microtubules, thereby providing spacing in the cytoskeleton. Another subcategory of entropic chains are entropic springs, 
such as those present in the titin protein, which contains repeat regions rich in PEVK amino acids that generate force upon 
over-stretching to help restore muscle cells to their relaxed length.60,61 
 
2.2. Display sites 
Post-translational modifications (PTMs) affect the stability, turnover, interaction potential and localization of proteins 
within the cell.62 These aspects of PTMs are particularly relevant for proteins involved in regulation and signaling, as are 
many IDPs.35,36,38,63,64 The conformational flexibility of disordered protein regions as display sites provides obvious 
advantages over structured regions. Flexibility facilitates (i) the deposition of PTMs by enabling transient but specific 
interaction with catalytic sites of modifying enzymes, and (ii) easy access and recognition by PTM-binding proteins that 
mediate downstream outcomes upon binding.46,65 Indeed, experimental and computational approaches have shown that 
disordered regions are enriched for sites that can be phosphorylated.44,45,66 Results of computational studies suggest that 
IDPs are likely to be substrates of a large number of kinases and other modifying enzymes as they are heavily post-
translationally modified.45,67,68 Furthermore, PTM sites are often located within short peptide motifs, modification of which 
influences the affinity for interaction with diverse binding partners (see section 3.1.).69,70 In turn, disordered protein regions 
are strongly enriched for these motifs,46,71-73 underlining the importance of intrinsic disorder as PTM display sites. Well-
characterized examples of IDPs in which PTMs are key to function and regulation include, among others, histones, p53, and 
the cyclin-dependent kinase regulator p27.74-76 
 
2.3. Chaperones 
Chaperones are proteins that assist RNA and protein molecules to reach their functionally folded states.77,78 Statistical 
analysis showed that disordered regions make up over half of RNA chaperones and over a third of protein chaperones.79,80 
The versatility of disordered segments seems extremely suitable for chaperone mechanics, although mechanistic evidence is 
still scarce.81 Firstly, their capacity to adapt to many different binding partners matches the need for chaperones to bind a 
wide range of proteins. Secondly, disordered segments enable quick interactions, for example preventing misfolded proteins 
from forming toxic aggregates by binding them quickly. Finally, the binding thermodynamics of disordered regions are well 
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suited for the cycles of repeated chaperone binding and release that enable substrate folding. It has been proposed that 
binding of disordered chaperone regions to misfolded substrates induces local folding of the disordered chaperone, and 
promotes unfolding of the substrate, thereby providing the substrate with a chance to refold correctly. This reversible 
exchange of entropy between chaperone IDRs and misfolded substrates forms the basis of the entropy transfer model79 and 
represents a distinct type of chaperone function that relies on disordered regions and does not require ATP. This mechanism 
can even be switched on and off at need by regulated transitions between folded and disordered states, as reported in the 
case of the redox-regulated chaperone Hsp33.82 
 
2.4. Effectors 
Another functional class of disordered regions is that of the effectors, which interact with other proteins and modify their 
activity. Upon binding their interaction partners, IDRs often show a disorder-to-order transition, also known as coupled 
folding and binding.83,84 Examples of two effectors that fold upon binding are p21 and p27, which regulate different cyclin-
dependent kinases (Cdk) that are responsible for the control of cell-cycle progression in mammals.65 p21 and p27 exhibit 
functional diversity by achieving opposite effects on different Cdk-cyclin complexes; promoting the assembly and catalytic 
activity of some (e.g. Cdk4 paired with D-type cyclins), and inhibiting others (e.g. Cdk2 paired with A- and E-type 
cyclins).65 Another effector IDP is calpastatin, which undergoes significant folding upon binding calpain, thereby achieving 
specific and reversible inhibition.85 Effector IDRs can also affect the activity of other parts within the same protein for 
example to achieve auto-inhibition. The intrinsically disordered GTPase-binding domain (GBD) of the Wiskott–Aldrich 
syndrome protein (WASP) illustrates such behavior.86 Binding of the GBD to the Cdc42 protein promotes interaction of 
WASP with the actin cytoskeleton regulatory machinery. However, GDB adopts a different structure when it folds back on 
other parts of WASP to inhibit actin interaction. More generally, autoinhibitory regions are indeed enriched for intrinsic 
disorder and often have different structures in the inhibitory and active states of the protein.87 
 
2.5. Assemblers 
Disordered assemblers bring together multiple binding partners to promote the formation of higher-order protein complexes, 
such as the ribosome (many ribosomal proteins are disordered88), activated T-cell receptor complexes and the transcription 
preinitiation complex.57,89 The presence of multiple molecular recognition features (MoRFs) and short linear peptide motifs 
(SLiMs) within the disordered segments enables binding and can bring together different partners (see section 3.1. and 
3.2.). Indeed, larger complexes are assembled from proteins that tend to be more disordered90 and intrinsic disorder is a 
common feature of hubs in protein interaction networks.91,92 The open structure of disordered assemblers is largely 
preserved upon scaffolding their partner proteins, resulting in a large binding interface that enables multiple proteins to be 
bound by a single IDR.93 Furthermore, intrinsic disorder avoids the problem of steric hindrance that prevents the formation 
of comparably large complexes from structured proteins. Assembler function can be imagined in two ways: (i) as structural 
mortar that helps bring together proteins by stabilizing the complexes they form, and (ii) as a scaffold that serves as 
backbone for the spatio-temporally regulated assembly of different signaling partners, allowing mediation of signaling 
events as initiated by specific stimuli and external conditions. An example of the latter mechanism is the axis inhibition 
(Axin) scaffold protein, which colocalizes β-catenin, casein kinase Iα, and glycogen synthetase kinase 3β by their binding to 
Axin's long intrinsically disordered region, thereby effectively yielding a complex of structured domains with flexible 
linkers.94 The assembly of all four proteins accelerates interactions between them by raising their local concentrations and 
leads to the efficient phosphorylation and subsequent destruction of β-catenin. Scaffolding regions have one of the highest 
degrees of disorder of all function categories.95,96 
 
2.6. Scavengers 
The final distinct function class of IDRs and IDPs are scavengers, which store and neutralize small ligands.  Chromogranin 
A, one of the earliest examples of an IDP, functions as a scavenger by storing ATP and adrenaline in the medulla of the 
adrenal gland.97 NMR studies showed that chromogranin is a random coil in both the isolated form and in its cellular 
environment in the intact adrenal gland.97 Other examples of scavenger IDPs are casein, a protein that binds clusters of 
calcium phosphate, and salivary proline-rich glycoproteins, which bind tannin molecules in the digestive tract.33 
 
3. Functional features 
Different types of functional regions in intrinsically disordered proteins have been uncovered both by investigations aimed 
directly at increasing the understanding of IDRs, and indirectly by linking previously studied functionality of proteins to 
disordered regions. First, the majority of linear motifs (such as the SH2 domain interaction motif) have been found as 
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enriched in IDRs.47,71,98 Second, the development of disorder prediction methods has led to the identification of segments 
that promote disorder-to-order transitions,99-103 which have been verified using known crystal structures. Third, some 
interaction domains identified using crystallography, by sequence analysis, and by other techniques, turn out to be 
intrinsically disordered in solution (e.g. the BH3 domain104). The following section discusses these three interaction features 
separately and points out the underlying connections between them. 
 
3.1. Linear motifs 
A common functional module within IDRs is the linear motif,46,47,71 also known as LMs, short linear motifs (SLiMs),105 or 
MiniMotifs.106 By regulating low-affinity interactions, these sequence motifs (annotated instances are usually 3-10 amino 
acids long47) target proteins to a particular subcellular location, recruit enzymes that alter the chemical state of the motif by 
post-translational modifications (PTMs), control the stability of a protein, and promote recruitment of binding factors to 
facilitate complex formation.46,47 Linear motifs, helped by the flexible nature of the disordered regions that surround them,71 
primarily bind onto the surfaces of globular domains107,108 and their compact binding surface promotes them to occur 
multiple times within one protein.46,47 Moreover, the short nature of many linear motifs means they have a high propensity 
to convergently evolve and emerge in unrelated proteins.46,47 A consequence of these properties is that pathogenic viruses 
and bacteria have evolved to mimic these linear motifs, allowing them to manipulate regulation of cellular processes.109,110 
 
Linear motifs can be broadly divided into two major families: those that act as modification sites and those that act as 
ligands, with each having numerous subgroups (Van Roey et al. Chemical Reviews, same issue) (Figure 6). The first major 
family, the enzyme binding or modification motifs, can be divided into three groups. (i) Post-translational processing events 
or proteolytic cleavage. A well-known example is the motif recognized by Caspase-3 and -7, which has a [ED]xxD[AGS] 
consensus sequence. Caspases are a family of proteases that promote apoptosis and inflammation by cleaving such motifs in 
their substrate proteins.111 Hundreds of proteins have convergently evolved the Caspase-3/-7 motif to become under the 
regulation of the apoptotic pathway.112 (ii) PTM moiety removal and addition. Post-translational modifications are often 
catalyzed by enzymes, many of which recognize a specific binding sequence. For example, the cyclin-dependent kinase 
recognition motif, [ST]Px[KR], is present in many mitotic proteins and its phosphorylation is key for regulating cell cycle 
progression.113 (iii) Structural modifications. This group of motifs is involved in the catalyzed conformational alteration of a 
peptide backbone. The classic example is the peptidylprolyl cis-trans isomerase (PPIase) Pin1, which binds [ST]P motifs in 
a phosphorylation dependent manner to catalyze the cis-trans isomerization of the proline peptide bond. This modification 
can regulate the recognition of [ST]P phosphorylated sites by phosphatases.114 
 
The second major family of motifs are the ligand motifs, which can also be divided into three main groups (Figure 6). (i) 
Complex promoting motifs are the most well-known class of motifs and include the phosphorylated tyrosine motif 
recognized by SH2 (Src homology 2) domains, the C-terminal motifs that bind PDZ domains, and the proline-rich PxxP 
motifs that interact with SH3 (Src homology 3) domains.115 These motifs often function in protein scaffolding and their 
multivalency (tendency to occur multiple times in one sequence) can increase the avidity of interactions promoting phase 
transition (see section 9.1.).116 (ii) Docking motifs increase the specificity and efficiency of modification events (e.g. 
addition or removal of PTMs, see above) by providing additional binding surface. These motifs are distinct from the 
modification sites and are usually (but not always117) in the same protein. Examples include the degron motifs (KEN box, D 
box, F box), which act as recognition surfaces for ubiquitin ligases and often function to regulate protein degradation by the 
26S proteasome.117-119 The KEN box motif occurs in several key mitotic kinases to ensure their degradation or deactivation 
at mitotic exit.119 (iii) Targeting motifs can localize proteins towards subcellular organelles. For example, importin proteins 
of the nuclear pore complex recognize the nuclear localization signal (NLS), usually a motif containing a short cluster of 
lysines and arginines, and translocate NLS-containing proteins into the nucleus.120 Targeting motifs can also act to traffic 
proteins, as in the case of motifs recognized by adaptor proteins at different stages of endocytosis, which ensure that 
vesicles are trafficked to the right location.121 
 
An important feature of linear motifs is their propensity to act as molecular switches. This is for two major reasons: (i) 
linear motif-mediated interactions are low affinity, which means that large, bulky post-translational modifications will alter 
their the binding properties;70 (ii) their small footprint (or surface area) allows motifs to occur multiple times in one 
sequence promoting high avidity interactions and the recruitment of multiple factors (e.g. the LAT complex in T-cell 
receptor signaling122). This also means two motifs can overlap resulting in mutually exclusive binding.72  The ability of a 
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motif to rapidly switch between binding partners and create multivalent complexes is crucial for the creation of dynamic 
signaling networks.70 
 
3.2. Molecular recognition features 
Disordered segments can also contain another type of peptide motif (10–70 amino acids) that promotes specific protein–
protein interactions. These functional elements are called preformed structural elements (PSEs),99 molecular recognition 
features (MoRFs) or elements (MoREs),100-102 or prestructured motifs (PreSMos).103 Importantly, MoRFs undergo disorder-
to-order transition upon binding to their interaction partners (i.e. folding upon binding),37,101,103 and often the unbound form 
of these preformed elements is biased towards the conformation that they have in complex.99 Preformed structural elements 
and MoRFs may serve as initial contact points for interaction events, which have different kinetic and thermodynamic 
properties than interactions between structured protein regions. Binding of preformed elements is one version of 
conformational selection (see section 6.), suggested long ago for interactions with flexible ligands.123 At the other extreme 
is coupled binding and folding, or induced fit, in which structure formation and binding occur concomitantly after the 
formation of the initial encounter complex. Given the complexity of many complexes involving intrinsically disordered 
partners, interactions involving both conformational selection of preformed elements and induced fit likely occur.84,124   
 
MoRFs occurring in the Protein Data Bank125 can be classified into subtypes according to the structures they adopt in the 
bound state: α-MoRFs, β-MoRFs, and ι-MoRFs (Figure 7A-C),101 which form α-helices, β-strands, and irregular secondary 
structure when bound, respectively. MoRFs that contain combinations of different types of secondary structure are called 
complex (Figure 7D).101 The p53 protein contains multiple MoRFs that are disordered in the absence of their interactors 
(Figure 7E).100,101 The first p53 MoRF is located near the N-terminus and undergoes a transition from a disordered to an α-
helical state upon interaction with the Mdm2 protein. In fact, this region of p53 exemplifies the high potential of IDRs for 
multiple partner binding as it is known to bind more than 40 different partners, although for most of these complexes the 3D 
structures are not determined and therefore the MoRF type is not always known. The region between p53 residues 40 and 60 
features an α-MoRF that functions as a secondary binding site for Mdm2 as well as a primary binding site for RPA70.126 In 
the absence of any binding partner, this region shows evidence of minimal helical secondary structure,127 whereas bound to 
either Mdm2128 or RPA70129 stronger helical structures are formed. The C-terminal region of p53 also contains a MoRF that 
interacts with multiple partners, giving rise to different bound structures. For example, the S100B(ββ) protein induces a 
helical structure, while interaction with the Cdk2-cyclin A complex leads to an irregular ι-MoRF. An example of the role of 
MoRFs in scaffolding proteins is RNase E, which assembles the RNA degradosome.130 The flexible C-terminal end of 
RNase E contains several recognition motifs that are central to its scaffolding function and serve as binding sites for other 
members of the degradosome.131 For example, an α-MoRF interacts with enolase132 and a β-MoRF binds polynucleotide 
phosphorylase.133 The recognition features are connected by disordered segments that accommodate assembly of the 
complex by providing flexibility. Lee and co-workers103 have annotated the secondary structure propensities of many other 
regions that display transient structural elements and undergo disorder-to-order transitions, all of which have been 
experimentally confirmed by NMR spectroscopy.  
 
Sequence context can play an active role in modulating the degree of structural pre-organization of a MoRF. An example 
pertains to the study of DNA binding motifs in the basic regions (bRs) of basic region leucine zipper transcription factors.134 
The bRs are 28-30 residues long regions predicted to be highly disordered and include a strongly conserved ten-residue 
DNA binding motif (DBM). The α-helicity (i.e. preference for α-helical conformation) of the DBM in the unbound form is 
modulated by the sequence of the N-terminal segment that is directly in cis to the DBM.134 For example, the N-terminal 
sequence contexts of Gcn4 and Cys3 DBMs contribute to a higher level of helicity of the DBM than the same region in c-
Fos and Fra1 (whose DBMs have a low helicity). Essentially, the N-terminal sequence contexts are helix caps and these can 
be used in different ways to ensure different levels of structural pre-organization within an α-MoRF, thereby suggesting that 
sequence contexts can provide useful clues when classifying MoRFs and linear motifs.135 
 
3.3. Intrinsically disordered domains 
Most protein domains that are identified using sequence-based approaches are structured, but some can be fully or largely 
disordered136 or contain conserved disordered regions137 known as intrinsically disordered domains (IDDs). For instance, 
about 14% of Pfam domains have more than 50% of their residues in predicted disorder, and many well-known domains, 
such as the kinase-inhibitory domain (KID) of Cdk inhibitors (e.g. p2765) and the Wiskott–Aldrich syndrome protein 
(WASP)-homology domain 2 (WH2) of actin-binding proteins136 have been shown experimentally to be fully disordered. 
Protein domains with conserved disordered regions have a variety of functions, but are most commonly involved in DNA-, 
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RNA- and protein binding.137 Furthermore, domains that were gained during evolution by the extension of existing exons 
contain the highest degree of disordered regions.138 This suggests that exonization of previously non-coding regions could 
be an important mechanism for the addition of disordered segments to proteins. 
 
Interestingly, it has also been observed that particular disordered regions frequently co-occur in the same sequence with 
specific protein domains.139,140 Some domain families appear only to require the presence of disorder in their neighborhood 
for functioning, while others seem to rely on the occurrence of disordered regions in specific locations relative to the start or 
end of the protein domain.139 For example, particular combinations of domains, involved mainly in regulatory, binding, 
receptor, and ion-channel roles, only occur with a disordered region inserted between them, while others only occur without 
a disordered domain between them. These observations imply that short disordered regions in the vicinity of protein 
domains complement the function of a structured domain, and in some cases may comprise separate functional domains in 
their own right. Thus, the co-occurrence of IDRs and structured domains in the same protein might be useful to gain insight 
into unannotated disordered regions. 
 
3.4. Continuum of functional features 
A measure that is often used to distinguish the different types of disordered binding modules is length, however this is likely 
to stem primarily from the different methodology used for their detection. Protein domain detection relies on hidden 
Markov models,22 which are poor at identifying short sequences, and therefore domain annotation tends to focus on larger 
binding modules. In contrast, linear motifs in the ELM database105 (based on which average linear motif length is defined) 
are biased towards short binding modules as these more straightforward to annotate. Finally, the tendency of MoRFs and 
preformed elements to undergo disorder-to-order transition and the statistics used for their detection, means that these 
features tend to be slightly longer than annotated linear motifs. 
 
Thus, although there are differences in the definitions of linear motifs and MoRFs, they share many common features71,141 
including a tendency to undergo disorder-to-order transition (all MoRFs by definition and 60% of LMs47), an enrichment in 
IDRs (MoRFs by definition and 80% of LMs are in IDRs47,71), and a tendency to promote complex formation.47,102 
Intrinsically disordered domains can also have significant overlap with MoRFs and linear motifs. For example, the WH2 
domain is considered an IDD136 and is also defined as a motif in the ELM database.105 One feature that is probably unique to 
IDDs is that some are not only capable of binding to well-folded, structured domains (a mechanism shared with motifs and 
MoRFs), but can also bind each other in a process of mutually induced folding. For example, the nuclear coactivator 
binding domain (NCBD) of CREB-binding protein (CBP) and the activator for thyroid hormone and retinoid receptors 
(ACTR) domain of p160 are both disordered on their own but upon interaction form a complex by mutual synergistic 
folding.142 The overlap between especially linear motifs and MoRFs, but also IDDs, suggests that these functional features 
are different states in the same continuum of binding mechanisms involving disordered regions. 
 
4. Structure 
Intrinsically disordered regions and proteins show a wide variety of structural subtypes. These different types of disorder 
can be characterized using an array of experimental techniques (Box 2) and several resources collect computationally 
identified and experimentally verified disordered regions (Box 1). The following section discusses classification schemes 
that are based on structural features of disordered proteins. 
 
4.1. Structural continuum 
Proteins have been proposed to function within a conformational continuum, ranging from fully structured to completely 
disordered.36 The spectrum covers tightly folded domains that display either no disorder or only local disorder in long loops 
or tails, multidomain proteins linked by disordered regions, compact molten globules containing extensive secondary 
structure, collapsed globules formed by polar sequence tracts, unfolded states that transiently populate local elements of 
secondary structure, and highly extended states that resemble statistical coils (Figure 8). In this model, there are no 
boundaries between the described states and native proteins could appear anywhere within the continuous landscape. IDRs 
are highly dynamic and fluctuate rapidly over an ensemble of heterogeneous conformations.143 Thus, an IDR may fluctuate 
stochastically between several different states, transiently sampling coil-like states, localized secondary structure, and more 
compact globular states. Transient localized elements of secondary structure (most often helix) are common in amphipathic 
regions of the sequence and this potentially plays a role in binding processes.84 The structural characteristics and 
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populations of the individual states in the conformational ensemble and the degree of compaction of the polypeptide chain 
are determined by the nature of the amino acids and their distribution in the IDR sequence (see section 5.1.).144,145 
 
4.2. Protein quartet 
The protein quartet model proposed by Uversky suggests that protein function can arise from four types of conformational 
states and the transitions between them (Figure 9). The conformational states can be classified as random coil, pre-molten 
globule, molten globule, and folded.34 In this model, unbound disordered regions could fall into all categories except for 
‘folded’. Originally it was shown that IDPs can realize extended conformations (i.e. random coil-like) or remain globally 
collapsed (i.e. molten globule-like) with regions of fluctuating secondary structure.32 Hydrodynamic radii and far-UV 
circular dichroism (CD) experiments revealed that random coil-like IDPs can be further subdivided into intrinsic pre-molten 
globules and intrinsic coils.34 Proteins in the pre-molten globule state are less compact than molten globules, but still show 
some residual secondary structure. In contrast, proteins in the intrinsic coil state show little or no secondary structure. The 
average net charge in part determines the conformational state of a disordered region, with low and high average charges 
corresponding to disordered globules and swollen coils, respectively (see section 5.1.).144,145 Furthermore, the pre-molten 
globule state has a high propensity to participate in folding upon binding events,146 which would make this structural state 
suitable for disordered regions acting as effectors and scaffolds. Thus, IDRs are able to undergo structural transitions, for 
example upon binding to partner molecules, with conformational rearrangements varying across the whole range of 
conformational states. The quartet model was further extended based on the notion that IDPs and IDRs possess remarkable 
structural and sequence heterogeneity. IDRs may be considered as modular assemblies of foldons (independently foldable 
regions), inducible foldons (foldable regions that can gain structure as a result of interaction with specific partners), semi-
foldons (regions that are always partially folded), and non-foldons (regions that that do not fold at all).147 In other words, as 
described previously in the structural continuum model (see section 4.1.),36 there is a continuous spectrum of differently 
disordered conformations extending from fully ordered to completely structure-less proteins, with everything in between. 
 
FG nucleoporins are an example of the functional significance that different disordered conformations can have. The porins 
make up the central part of Nuclear Pore Complexes (NPCs) and regulate nucleocytoplasmic transport.148 Intrinsically 
disordered regions with multiple phenylalanine-glycine (FG) motifs make up large parts of the NPC gates. FG domains 
adopt various disordered conformations with specific functions.149 Some domains have the low charge characteristics of 
collapsed coils, while others are characterized by a high degree of charged amino acids, giving rise to relaxed and extended 
coil structures. Molecular dynamics simulations have shown that extended coils are more dynamic than collapsed coils, 
suggesting distinct functionalities for the two structural groups. Interestingly, some FG nucleoporins feature both types of 
disorder along their polypeptide chain. Combinations of disorder subtypes in nucleoporin domains are likely to contribute to 
NPC gating behavior by creating ‘traffic’ zones with distinct physicochemical properties that influence the dynamics of 
substrate translocation through the nuclear envelope.149-152 
 
4.3. Supertertiary structure 
IDRs allow for complex regulatory phenomena, as witnessed in the case of multidomain proteins in signaling and 
regulation. Due to the presence of structural disorder, functional domains and short motifs, multidomain proteins are 
characterized by a dynamic ensemble of tertiary conformations. Some conformations are dominated by intra-molecular 
domain-domain and domain-motif interactions and are closed and structured in nature, while other conformations are more 
open and disordered. This state of intra-molecular and conformational variability lays in between the tertiary structure of 
domains and quaternary structure of multiprotein assemblies, and has been termed supertertiary structure.153 Complex 
regulatory function stems from transitions in the ensemble of these structures, as witnessed in the case of several well 
characterized proteins, such as the Wiskott–Aldrich syndrome protein (WASP, see section 2.4.),86 the Src-family tyrosine 
kinase Hck,154 and the E3 ubiquitin ligase Smurf2.155 
 
5. Sequence 
The sequences of IDPs and IDRs have distinct compositional biases such as the enrichment in charged and polar amino 
acids and deficiency of bulky hydrophobic groups.31,43,156,157 These biases have lead to the inference that disorder is a natural 
consequence of weakening the hydrophobic forces that drive folding of polypeptides into compact tertiary structures. 
Although disordered regions generally lack the ability to fold independently due to these biases in amino acid composition, 
within IDRs distinct subsets of sequences can be identified that have different structural and functional characteristics. The 
following section covers sequence-based classification schemes of IDRs. 
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5.1. Sequence-ensemble relationships 
Systematic efforts combining experiments and computations have addressed the relationship between information encoded 
in amino acid sequences and the ensemble of conformations these sequences can sample in different conditions. These 
studies have focused on three major archetype sequences, namely polar tracts, polyelectrolytes, and polyampholytes.158 
Polar tracts are sequence stretches enriched in polar amino acids such as glutamine, asparagine, serine, glycine, and proline 
and deficient in charged as well as hydrophobic residues. These polar tracts (especially glutamine, asparagine, and glycine-
rich sequences) form globules that are generally devoid of significant secondary structure preferences159-162 and can be as 
compact as well-folded domains.158 Collapse of polar tracts arises from the preference for self-solvation over solvation by 
the aqueous milieu and disorder derives from a lack of specificity for a single compact conformation as instead 
heterogeneous ensembles of conformations with similar stabilities and compactness are formed. In terms of the energy 
landscape,163 the free energy surface for polar tracts is weakly funneled and resembles an ‘egg carton’. Interestingly, the 
drive to collapse, which implies a drive to minimize the interface between the IDR and the surrounding solvent, can also 
give rise to the significant aggregation and solubility problems164 as is the case with several glutamine, asparagine, and 
glycine-rich sequences that are implicated in amyloid formation and phase separation.165 
 
Another end of the compositional spectrum are polyelectrolytes. Their amino acid compositions are biased toward charged 
residues of one type such as the arginine-rich protamines144 or the Glu/Asp-rich prothymosin α.145 Experiments and 
simulations have shown that the tendency of polypeptide backbones to form ensembles of collapsed structures can be 
reversed by increasing the net charge per residue past a certain threshold (Figure 10A). The transition between globules and 
expanded coils is sharp, suggesting that small changes to the net charge per residue through post-translational modifications 
such as serine or threonine phosphorylation or lysine acetylation can cause reversible globule-to-coil transitions. These 
transitions might control the accessibility of SLiMs and MoRFs or even modulate the conformations of these elements. 
 
The impact of the net charge per residue on the conformational properties of IDPs can be summarized in a diagram-of-states 
(Figure 10A),144 which generalizes the original charge-hydropathy plot.31 The diagram classifies IDPs based on their amino 
acid compositions. Annotation using curated disordered sequences from the DisProt database166 (Box 1)  suggests that a vast 
majority (~95%) of IDPs have amino acid compositions that predispose them to be globule formers (Figure 10A).167 This 
inference would imply that the majority of IDPs are unstable proteins that pose serious challenges for protein homeostasis, 
because globule-forming sequences do not fold autonomously and should be marginally soluble. Importantly however, a 
majority (~75%) of the predicted globule formers are actually polyampholytes in that they are enriched in charged residues 
but have roughly equal numbers of positive and negative charges. Although such sequences are classified as globule 
formers on the basis of their low net charge per residue, in reality the conformational properties of polyampholytes are 
governed by the linear sequence distribution of oppositely charged residues. If the oppositely charged residues are 
segregated in the linear sequence, then electrostatic attractions between oppositely charged blocks cause chain collapse and 
result in hairpin or globular conformations. In sequences with well-mixed oppositely charged residues, the effects of 
electrostatic repulsions and attractions counterbalance. These mixed sequences adopt random-coil or globular 
conformations, depending on the total charge (in terms of the fraction of charged residues) (Figure 10B). Many IDPs are 
strong polyampholytes with well-mixed linear patterns of oppositely charged residues.167 Thus, IDPs are actually enriched 
in different classes of random coils that form swollen, loosely packed conformations (Figure 10B). Such random-coil 
sequences are likely to help improve the solubility profiles of connected structured domains and to promote the flexibility 
that is required for functions like entropic tethers or bristles. These biophysical principles of sequence-ensemble 
relationships enable the use of de novo sequence design as a tool for modulating these relationships and assessing their 
impact on functions associated with IDPs and IDRs. 
 
5.2. Prediction flavors 
Methods to predict disorder from sequence can be classified into two categories:168,169 (i) methods that rely on the physical 
principles underlying protein folding and (ii) methods that are based on machine learning approaches (e.g. support vector 
machines or neural networks) and are trained on available experimental data which indicates the absence of structure in 
proteins (for instance, the lack of electron density in crystallographic data). Disorder prediction accuracy varies for different 
types of disordered regions.170 Some predictors accurately predict certain disordered regions but have low accuracy 
predicting others, whereas other predictors give opposite results. Vucetic and co-workers170 classified protein disorder into 
three different ‘flavors’ based on competition between disorder predictors. These V, C, and S disorder flavors 
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(corresponding to the names of the disorder predictors that best predict them: VL-2V, VL-2C, and VL-2S) show differences 
in sequence composition and combinations of flavors could be associated with different protein functions. For example, 
disordered regions that bind to other proteins are enriched for flavor S, while disordered ribosomal proteins belong to flavor 
V. Flavor C gave strong disorder predictions for sugar binding domains. 
 
5.3. Disorder-complexity space 
The relationship between sequence complexity and disorder propensity provides further insight into the structural and 
function variations of IDRs.171 Different function classes of proteins often show a different disorder-complexity (DC) space 
distribution. A frequently observed DC-trace is composed of a compact structured region and a section extending out into 
low complexity, disordered space before looping back into the structured region. This pattern describes a disordered region 
acting as a linker between structured domains. An example is the bacterial translation initiation factor, which has a 
disordered linker that appears in the DC-trace as a low-complexity, disordered loop connecting the N- and C-terminal 
structured, high-complexity domains.171,172 Thus, functionally related proteins have similar disorder-complexity 
distributions, suggesting that these distributions might be useful for predicting the function of a disordered region. 
 
5.4. Overall degree of disorder 
Large-scale studies into IDP function often group the proteins based on some measure of disorder. For example, protein 
sequences have been categorized based on the overall degree of disorder or fraction of residues that are shown or predicted 
to be disordered,67,173 resulting in e.g. groups of structured proteins (0-10% disorder), moderately disordered proteins (10-
30% disorder), and highly disordered proteins (30-100% disorder). Other studies classified proteins based on an overall 
score of disorder for the whole protein,174 and the presence or absence of continuous stretches of disordered residues with a 
specific length.35,50,139,173 Largely structured proteins are enriched for e.g. metabolic functions, while highly disordered 
proteins function predominantly in regulation. Hence, classification of disordered proteins based on the level of disorder 
provides clues about what types of functions are likely. 
 
5.5. Length of disordered regions 
The length of IDRs in human follows a power law distribution: there are large numbers of short disordered regions and 
increasingly smaller numbers of longer ones.175 Other eukaryotic and prokaryotic proteomes show similar disorder length 
profiles. Short IDRs may function as linkers and contain individual linear motifs or MoRFs, whereas longer disordered 
regions might be entropic chains or contain combinations of motifs or domains functioning in recognition. Long disordered 
regions (more than 500 residues) are typically over-represented in transcription-related functions,176 whereas proteins 
containing IDRs of intermediate length (300-500 residues) are enriched for kinase and phosphatase functions. Short IDRs 
(less than 50 residues) tend to be linked to metal ion binding, ion channel, and GTPase regulatory functions. Thus, the 
length of a disordered region can also provide a useful indication about the function of the protein containing it. 
 
5.6. Position of disordered regions 
Almost all human proteins have some disordered residues within their terminal regions.58 For example 97% of proteins have 
predicted disorder in the first or last five residues.139 Disordered N-terminal tails are common in DNA-binding proteins, and 
have been shown to contribute to efficient DNA scanning.177 Furthermore, proteins that are relatively rich in disordered 
residues at the C-terminus are often associated with transcription factor repressor and activator activities compared to 
proteins rich in internal or N-terminal disorder.176 Ion channel proteins in turn are enriched for disordered residues at the N-
terminus and the same is true to lesser extent for C-terminal disorder.176 Indeed, voltage-gated potassium channels often 
contain disordered residues at their termini, some of which are responsible for channel inactivation.178 Finally, proteins that 
are relatively rich in internal disordered regions are weakly enriched for transcription regulator and DNA binding activity.176 
Thus, the relative position of a disordered region in a sequence provides clues about the function of the protein containing it. 
 
5.7. Tandem repeats 
Short tandem repeats are common in IDRs and IDPs.60,179 A study comparing the overlap between amino acid repeats and 
disordered regions demonstrated that most tandem repeats are associated with disordered regions.180 For instance, as much 
as 96% of polyglutamate and polyserine stretches lie within IDRs. Similarly large fractions were found for proline, glycine, 
glutamine, lysine, aspartate, arginine, histidine, and threonine repeats. In contrast, polyleucine stretches occur 
predominantly within structured regions. These observations agree with the compositional bias of disordered regions; the 
most common tandem repeats in IDRs are made up of disorder-promoting residues43,156 and of sequence patterns that are 
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typically associated with disorder.157 Moreover, a distinction between perfect and imperfect tandem repeats suggests that as 
the repeat perfection increases, so does the disorder content.179 
 
Repeats of different composition have been linked to specific functions. Consequently, the presence of particular types of 
repeats is likely to contribute to IDR functioning. Descriptions and examples of different classes of disordered tandem 
repeats and their structural characteristics have been published previously.181 For instance, polyproline and polyglutamine 
stretches are associated with protein- and nucleic acid binding and transcription factor activity.182,183 Protein segments 
enriched for glutamine and asparagine often occur in disordered regions184 and are abundant in eukaryotic proteomes,185 
despite their propensity to aggregate or form coiled-coil structures.186 The aggregation propensity of the Q/N-enriched 
segments has been exploited to mediate the formation of different, physiologically relevant assemblies such as P-bodies 
(e.g. Ccr4 and Pop2), stress granules and processing bodies,187 but expanded polyglutamine repeats have also been 
associated with neurodegenerative disorders, the most well known being Huntington’s disease.188 Moreover, several prion-
like yeast proteins (e.g. Sup35p and Ure2p) contain intrinsically disordered Q/N-rich protein segments that have been 
implicated in the switch between a soluble and an insoluble, aggregated, form.185,189 Another example of functional 
disordered repeats occurs in the SR protein family of splicing factors (e.g. ASF/SF2 and SRp75).190,191 SR proteins mediate 
assembly of spliceosome components and consist of an N-terminal RNA-recognition motif and a disordered C-terminus 
with tandem repeats of arginine and serine residues (RS domain). The RS domain is phosphorylated192 and predicted to be 
largely disordered,190 suggesting that the intrinsic disorder in the RS domain facilitates recruitment of spliceosome 
components. Other disordered repeats associated with specific function include repeats of lysine, alanine, and proline in the 
histone H1 C-terminal domain, which are involved in the formation of 30nm chromatin fiber by binding linker DNA 
between the nucleosomes.193 Some of these repeats also have the propensity to undergo phase transition from a soluble 
monomeric state to an insoluble large assembly form (see section 9.1.) 
 
6. Protein interactions 
Disordered regions in the native unbound state exist as dynamic ensembles of rapidly interconverting conformations,143,194 
which can be described by an energy landscape.195 Conditions, post-translational modifications and binding events change 
the energy levels of individual conformations as well as the relative energies between conformations.196-198 As a result, the 
contribution of individual conformations to the protein ensemble changes under different conditions. For example, addition 
of specific binding partners can result in a population shift in the ensemble towards the conformation that is most favorable 
for binding; a phenomenon referred to as conformational selection.99,123,196,198 This mechanism has been observed in both 
protein-protein and protein-nucleic acid interactions.196 
 
Intrinsic disorder-mediated molecular interactions have been proposed to work using a combination of conformational 
selection and induced folding (i.e. when a protein undergoes a disorder-to-order transition upon association with its binding 
partner).84,124 These mechanisms of binding are two extreme possibilities and are not mutually exclusive. Both play a role in 
the interaction between two proteins, the dominant mechanism depending for example on the concentrations of the 
individual proteins.199 Evidence for the role of conformational selection in IDP binding comes from the interaction between 
PDEγ and the α-subunit of transducin,200 which is important in phototransduction. The dynamic ensemble of unbound PDEγ 
includes a loosely folded state that resembles its structure when bound to transducin. Evidence for the role of induced 
folding, or coupled folding and binding, comes from a study investigating the disordered pKID region of CREB and the 
KIX domain of CREB-binding protein. Upon binding of pKID to the KIX domain, an ensemble of transient encounter 
complexes forms, which appear to be stabilized primarily by hydrophobic contacts and evolve to form the fully bound state 
via an intermediate state without disassociation of the two domains.83,201 
 
6.1. Fuzzy complexes 
Although disordered protein regions frequently fold upon interaction with other proteins, complexes with IDPs often retain 
significant conformational freedom and can only be described as structural ensembles.202 The conformations that disordered 
proteins adopt in the bound state cover a continuum, similar to the structural spectrum of free, unbound IDPs,203 and ranges 
from static to dynamic, and from full to segmental disorder.202 In static disordered complexes, disordered regions can adopt 
multiple well-defined conformations in the complex, whereas in dynamic disorder they fluctuate between various states of 
an ensemble. 
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Disorder in the bound state can be classified into four molecular modes of action, each of which is associated with specific 
molecular functions (Figure 11A-D).202,204 (i) The polymorphic model is a form of static disorder, with alternative bound 
conformations serving distinct functions by having different effects on the binding partner. Examples are the Tcf4 catenin 
binding domain205 and the WH2 binding domain of e.g. thymosin β4 and Ciboulot,206 which have been shown to adopt 
several distinct conformations upon β-catenin and actin binding, respectively. Different actin-WH2 domain complexes have 
alternative interaction interfaces and result in actin polymers with different topologies.206 The (ii) clamp and (iii) flanking 
models represent forms of dynamic disorder in which complex formation either involves folding upon binding of two 
disordered segments that are connected by a linker that remains disordered, or the reverse situation, respectively. The 
cyclin-dependent kinase (Cdk) inhibitor p21 for example acts as a clamp. It contains a dynamic helical subdomain that 
serves as an adaptable linker that connect two binding domains and enables these to specifically bind distinct cyclin and 
Cdk complex combinations.207 In both the clamp and flanking models, disordered regions near the interacting protein 
segments (often short peptide motifs) contribute to binding by influencing affinity and specificity.202,208 This phenomenon 
relates to the importance of the sequence context in modulating disordered binding elements (see section 3.). Finally, (iv) 
the random model is an extreme version of dynamic disorder in protein complexes, which occurs when the IDR remains 
largely disordered even in the bound state. In this case, interaction is achieved via linear motifs that do not get fixed upon 
binding. An example is the self-assembly of elastin, where solid-state NMR has provided evidence for dynamic disorder 
within elastin fibers as they exhibit random-coil like chemical shift values.209 Another case is the complex between the Cdk 
inhibitor Sic1 and the SCF ubiquitin ligase subunit Cdc4, which is formed in a phosphorylation-dependent manner.210 At 
any given time, only one out of nine Sic1 phosphorylation sites interact with the core Cdc4 binding site, while the others 
contribute to the binding energy via a secondary binding site or via long-range electrostatic interactions (Figure 12O). 
Hence, binding interchanges dynamically within the Sic1-Cdc4 complex to provide ultra-fine tuning of the affinity.210 
 
Bound disordered regions can impact the interaction affinity and specificity of the complex and tune interactions of folded 
regions204 with proteins or DNA.211 Four different mechanisms have been proposed for the formation of fuzzy complexes 
(Figure 11E-H). (i) Conformational selection, when the disordered region shifts the conformational equilibrium of the 
binding interface towards the bound form. The fuzzy N-terminal tail of the Max transcription factor for example reduces 
electrostatic repulsion in the basic helix-loop-helix (bHLH) domain and thereby facilitates formation of the DNA 
recognition helices, which increases binding affinity by 10-100 fold.212 (ii) The disordered region(s) modulate flexibility of 
the binding interface. The serine- and arginine-rich region of the Ets-1 transcription factor exemplifies this mechanism and 
reduces DNA binding affinity by 100-1000 fold.213 (iii) Competitive binding of the disordered region. Here the IDR acts as 
a competitive inhibitor of other regions in the same protein for binding to a partner. The acidic fuzzy C-terminal tail of high-
mobility group protein B1 (HMGB1) negatively regulates interaction of the HMG DNA binding domains by occluding the 
basic DNA-binding surfaces.214 (iv) The disordered region serves to tether a weak-affinity binding region to increase its 
local concentration. For example, a fuzzy N-terminal domain anchors the human positive cofactor 4 (PC4) to herpes 
simplex virion protein 16 (VP16)215 and other trans-activation domains. All mechanisms of disordered complex formation 
affect binding to different degrees and can be further tuned by post-translational modifications.204,211 
 
6.2. Binding plasticity 
Structural analysis of a large number of intrinsic disorder-based protein complexes resulted in another categorization of 
IDRs based on their binding plasticity (Figure 12).216 Examples of relatively static IDR-based complexes are (i) mono- and 
polyvalent complexes, which typically show binding of disordered segments to one or multiple spatially distant binding 
sites on the interaction partners, respectively, (ii) chameleons, such as p53, that have different structures when binding to 
different proteins, (iii) penetrators that bury significant parts of the protein inside their binding partners, and (iv) huggers, 
which function in protein oligomerization, for example by coupled folding and binding of disordered monomers. In addition 
to these relatively static complexes involving IDRs, one can identify coiled-coil-based complexes. Regions that make up 
coiled coils are typically highly disordered in monomeric state and gain helical structure upon coiled-coil formation, giving 
rise to several distinguishable types of complexes, such as intertwined strings, connectors, armatures, and tentacles. 
 
7. Evolution 
Disordered regions typically evolve faster than structured domains.50-55,92 This behavior largely stems from a lack of 
constraints on maintaining packing interactions, which drives purifying selection in structured sequences.217 However, 
disordered residues do display a wide range of evolutionary rates (Box 3). The following section discusses the evolutionary 
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classifications of disordered protein regions. IDRs with similar function and properties tend to have similar evolutionary 
characteristics. 
 
7.1. Sequence conservation 
While the primary amino acid sequence of disordered regions evolves at different speeds, the property of disorder is usually 
conserved for functional sequences.53,137 Sequence conservation of IDRs varies according to their specific functions and 
provides another means for their classification.53,218,219 Three biologically distinct classes of IDRs with specific function 
were identified using a combination of disorder prediction and multiple sequence alignment of orthologous groups across 23 
species in the yeast clade (Figure 13): (i) flexible disorder describes regions where disorder is conserved but that have 
quickly evolving amino acid sequences (i.e. there is a requirement to be disordered, regardless of the exact sequence), (ii) 
constrained disorder describes regions of conserved disorder with also highly conserved amino acid sequences, and (iii) 
non-conserved disorder, where not even the property of being disordered is conserved in close species. For flexible disorder, 
low sequence conservation is expected if the property of disorder itself, as opposed to disorder in combination with specific 
sequence, is the only requirement for function. Examples of functions that mainly require the biophysical flexibility of 
disordered regions are entropic springs, spacers, and flexible linkers between well-folded protein domains.36,38,56,57 The 
linker in RPA70 is a clear example where the dynamic behavior is conserved even when the sequence conservation is low.59 
Flexible disorder is the most common of the three evolutionary classes (just over half of disordered residues in yeast) and 
appears to account for many of the characteristics traditionally associated with disordered regions, such as strong 
association with signaling and regulation processes,35,49,89,220-222 rapid evolution of primary sequence,50-55,92 the presence of 
short linear motifs (which are itself conserved, see below),46,71 and tight regulation (see section 8.).67,223 By contrast, 
constrained disorder (about a third of disordered residues in yeast) is associated with different properties and functions, such 
as chaperone activity and RNA-binding ribosomal proteins.53 Many proteins that contain the evolutionary constrained type 
of disorder can adopt a fixed conformation, suggesting that these regions might undergo folding upon binding to their 
targets. This structural transition might impose a high degree of local structural constraints, which results in constraints on 
the primary protein sequence alongside requirements to be flexible.53 Constrained disordered residues also occur more often 
in annotated protein sequence families (domains) than flexible disorder, but both types are strongly depleted in domains 
compared to structured regions. In human, both flexible and constrained disorder are enriched in proteins with functions 
related to differentiation and development.224 Finally, non-conserved disorder accounts for around 17% of disordered 
residues in yeast and appears to be largely non-functional. 
 
Short linear motifs (see section 3.1.)47,105 constitute a special case. Even though SLiMs almost exclusively lie within 
disordered regions, their own amino acid sequence tends to be conserved.47 These properties, together with the difficulty of 
aligning swiftly evolving disordered sequences, leads to the impression that motifs ‘move around’ when comparing their 
position in different sequences. In many ways, the disordered regions that contain SLiMs constitute flexible disorder as by 
the above classification, as their main role is to provide flexibility to enable access to the linear motif for proteins that will 
bind them as ligands225 or deposit post-translational modifications.46,47 Phosphorylation sites are closely related to short 
linear motifs that function in binding, but are often too short and weakly conserved to recognize via computational means.226 
More than 90% of sites phosphorylated by the yeast Cdk1 are in predicted disordered regions,66 as consistent with previous 
studies highlighting the importance of IDRs as display sites for phosphorylation and other PTMs.44,45 Comparison of the 
phosphorylation sites in orthologs of the Cdk1 substrates revealed that the precise position of most phosphorylation sites is 
not conserved. Instead, clusters of sites move around in the alignment of rapidly evolving disordered regions.68,227 Another 
example of the role of flexible disorder in signaling and regulation is the yeast serine-arginine protein kinase Sky1, which 
regulates proteins involved in mRNA metabolism and cation homeostasis. The Sky1 C-terminal loop is intrinsically 
disordered and contains phosphosites that are important for regulating its kinase activity.228 Conservation analysis has 
shown that the loop is conserved for disorder but not for sequence.53 
 
The combination of sequence conservation of IDRs and conservation of their amino acid composition between human and 
seven other eukaryotes (chimp, dog, rat, mouse, fly, worm and yeast) also identifies function preferences.219 IDRs with high 
residue conservation (HR) are enriched in proteins involved in transcription regulation and DNA binding. Low residue 
conservation in combination with high conservation of the amino acid type composition (LRHT) of the IDR (i.e. high 
similarity of overall amino acid composition between the human IDR and its orthologs) is often associated with ATPase and 
nuclease activities. Finally, IDRs which show neither conservation of sequence nor of composition (LRLT) are abundant in 
(metal) ion binding proteins. 
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7.2. Lineage and species specificity 
Increasingly complex organisms have higher abundances of disorder in their proteomes.35 An average of 2% of archaeal, 
4% of bacterial and 33% of eukaryotic proteins have been predicted to contain regions of disorder over 30 residues in 
length,35 although there is much variation within kingdoms.229,230 In human, 31% of proteins are highly unstructured67 and 
44% contain stretches of disorder longer than 30 residues.139,173 Human IDPs are spread relatively uniformly across the 
chromosomes, with percentages ranging from 38% (for genes encoding IDPs on chromosome 21) to 50% on chromosomes 
12 and X.139 A computational analysis of disorder in prokaryotes has corroborated the higher abundance of disorder in 
Bacteria as compared to Archaea.231 Moreover, in agreement with the low abundance of disorder in prokaryotes, none of the 
13 mitochondrial-encoded proteins are disordered.139 Systematic analysis of IDP occurrence in 53 archaeal species showed 
that disorder content is highly species-dependent.232 For example, Thermoproteales and Halobacteria proteomes have 14% 
and 34% disordered residues, respectively. Harsh environmental conditions seem to favor higher disorder contents, 
suggesting that some of the archaeal IDPs evolved to help accommodate hostile habitats.233 Furthermore, disorder is more 
common in viruses than in prokaryotes.234 The characteristics of IDRs seem well suited for especially small RNA viruses 
with extremely compact genomes.235,236 For example, disordered regions could buffer the deleterious effects of mutations 
introduced by low-fidelity virus polymerases better than structured domains would.234 The flexibility of IDRs to interact 
with many different proteins, such as proteins of the host immune system, is another benefit for compact viruses since it 
maximizes the amount of functionality they encode while minimizing the required genetic information.237 
 
In addition to the variation in prevalence of disordered regions between species, different kingdoms of life seem to use 
conserved IDRs for different functions: eukaryotic and viral proteins use disorder mainly for mediating transient protein-
protein interactions in signaling and regulation, while prokaryotes use disorder mainly for longer lasting interactions 
involved in complex formation.137 Thus, knowledge on the lineage, species and origin of a disordered region could help in 
predicting its likely function. 
 
7.3. History and mechanism of repeat evolution 
Tandem repeats are enriched for intrinsic disorder (see section 5.7.) and IDRs are increasingly abundant in increasingly 
complex organisms (see section 7.2.). The genetic instability of repetitive genomic regions in combination with the 
structurally permissive nature of IDRs might have driven the increase in the amount of disorder during evolution. 
Disordered repeat regions have been shown to fall into three categories, based on their evolutionary history and acquired 
functional properties (Figure 14):60 type I regions have not undergone function diversification after repeat expansion (e.g. 
the titin PEVK domain), type II comprises repeats that acquired diverse functions due to mutation or differential location 
within the sequence (e.g. the C-terminal domain of eukaryotic RNA polymerase II), and type III regions gained new 
functions as a consequence of their expansion per se (e.g. the prion protein octarepeat region). 
 
8. Regulation 
Altered availability of IDPs has been associated with diseases such as cancer and neurodegeneration.220,223,238-241 Indeed, 
genes that are harmful when overexpressed (i.e. dosage-sensitive genes) often encode proteins with disordered segments.242 
Multiple mechanisms at different stages during gene expression (from transcript synthesis to protein degradation) carefully 
control the availability of IDPs in order to minimize harmful effects.67 Their tight regulation ensures that IDPs are available 
in appropriate levels and for the right amount of time, thereby minimizing the likelihood of ectopic interactions. Disease-
causing altered availability of IDPs may result in imbalances in signaling pathways by sequestering proteins through non-
functional interactions involving disordered segments (i.e. molecular titration223). The next section discusses possible 
functional roles of proteins with IDRs based on their cellular regulatory properties such as transcript abundance, alternative 
splicing and degradation kinetics. 
 
8.1. Expression patterns 
Five different expression patterns were identified for transcripts encoding highly disordered proteins by investigating the 
mRNA levels from over 70 different human tissues and comparing the number of tissues in which IDP transcripts are 
expressed against the level of expression (Figure 15).173 The expression classes are associated with specific functions. (i) 
The first subgroup (Figure 15, light blue markers) shows constitutive high expression in all tissues and consists exclusively 
of large ribosomal subunit proteins, which are almost entirely disordered. (ii) The second group (blue-green) represents 
transcripts that show high expression levels in the majority of tissues. These often function as protease inhibitors, splicing 
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factors and complex assemblers. (iii) Moderately expressed transcripts (green) typically encode disordered proteins 
involved in DNA binding and transcription regulation. (iv) IDPs that are expressed in a tissue-specific manner (yellow) are 
enriched for cell organization regulators, transcription cofactors and factors that promote complex disassembly. Finally, (v) 
the remaining transcripts form a group (grey) not detected to be abundant in any of the tissues studied. This low and 
transient expression group contains more than half of the IDP transcripts analyzed and has a variety of functions (Figure 
15). 
 
8.2. Alternative splicing 
Trends in transcriptional regulation (alternative promotor and polyadenylation site usage) and post-transcriptional regulation 
(alternative splicing by inclusion or exclusion of exons) can also be informative of the role that specific disordered protein 
regions play in the cell (Figure 16). Alternatively spliced exons are overall more likely to encode intrinsically disordered 
rather than structured protein segments.139,243-245 This tendency is even more pronounced in alternative exons whose 
inclusion or exclusion is regulated in a tissue-specific manner.246 IDRs that are encoded by these tissue-specific alternative 
exons frequently influence the choice of protein interaction partners and can be instrumental in protein regulation246,247 by 
embedding (i) binding motifs and (ii) residues that can be post-translationally modified,246 however (iii) sole alternation in 
the length of a disordered region248 can also modulate the overall protein function (Figure 16). Changes in IDR length can 
be an effective mechanism for modifying the affinity of interactions that a protein makes, particularly in instances where a 
disordered region is responsible for the positioning of protein binding motifs or domains.249,250 Among the alternative exons, 
those that exhibit conserved splicing patterns across different species are particularly likely to have important regulatory 
roles. For example, tissue-specific exons, which are alternatively spliced in multiple different mammals, remarkably often 
contain IDRs with embedded phosphosites.251 Disordered regions these exons encode are hence likely to act as modulators 
of protein function depending on the tissue of gene expression.251 While tissue-specific exons that are alternatively spliced 
in a conserved fashion often code for phosphosites, the emergence of novel exons in a gene, although at first likely 
detrimental252 is a possible template for the evolution of short interaction motifs.253 Furthermore, changes in exon regulation 
can also be important for the emergence of novel adaptive functions. Accordingly, protein segments encoded by exons, 
which are alternatively spliced either in a single species or in a whole evolutionary lineage, are enriched in short binding 
motifs and alternative inclusion of disordered regions encoded by these exons is conceivably a source of evolutionary 
novelty.254 
 
In addition to the tendency of cassette alternative exons to frequently encode IDRs, exons adjacent to the alternatively 
spliced ones are also likely to code for disordered regions around the insertion point for the alternative segment.224,244 These 
disordered regions provide the structural flexibility that tolerates both presence and absence of the alternatively spliced 
segment, but they can also contain interaction motifs themselves.224 Furthermore, on the transcriptional level, diversity in 
protein isoforms can be created through both alternative splicing and usage of alternative promoters and polyadenylation 
sites. Protein segments that are encoded by the two latter mechanisms can contain disordered regions with motifs that define 
protein localization and stability.255 Taken together, these examples illustrate how better understanding of gene regulation 
and knowledge of evolutionarily conserved and novel patterns in transcript processing can provide insights into possible 
functional roles of whole proteins, but also individual protein regions. 
 
8.3. Degradation kinetics 
Another emerging functionality of disordered regions is their role in protein degradation.256-263 For example, protein half-life 
weakly correlates with the fraction of disordered residues67,259 and proteins that get ubiquitinated specifically upon heat 
shock stress are generally disordered.264 Although ubiquitination by E3 ligases has a dominant role in recruiting proteins to 
the proteasome for degradation,265,266 some IDRs of sufficient length seem to allow for efficient initiation of degradation by 
the proteasome independent of the ubiquitination status, as supported by in vitro experiments showing that degradation of 
tightly folded proteins is accelerated when a disordered region is attached to the substrate.257,263 Efficient degradation only 
occurs when the disordered terminal region is of a certain minimal length,263 but degradation may be initiated by IDRs 
either at the protein terminus or internally.256-263 Proteins that contain IDRs of sufficient length may therefore have increased 
turnover, although the exact length requirements will depend on the substrate. At the same time, not all IDRs influence 
protein half-life. For example disordered polypeptides with specific amino acid compositions can attenuate rather than 
accelerate degradation by the proteasome.267-269 The formation of proteins complexes or transient interactions with other 
proteins may also protect IDPs from degradation. Thus, we can distinguish a novel function class of IDRs: those that 
influence protein degradation (degradation accelerators) versus those that do not. These properties might be associated with 
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specific protein function. For example, proteins that contain IDRs of a given length are probably more susceptible to 
degradation, possibly linking them to functions of IDPs with low expression, although this is not necessarily the case. 
 
Some highly disordered proteins (e.g. p53, p73, IκBα, BimEL) can, at least in vitro, be degraded by the 20S proteasome 
independent of ubiquitination.270-275 Specialized proteins termed ‘nannies’ have been shown to bind to and protect IDPs 
from ubiquitin independent 20S proteasomal degradation.276 A free IDP, such as newly synthesized p53, might be degraded 
by the 20S proteasome, which leads to fast degradation kinetics. After a nanny binds the IDP (Hdmx in the case of p53), 
slower, ubiquitin-dependent degradation by the 26S proteasome takes place. This biphasic decay has been proposed as a 
way to distinguish structured proteins from IDPs and the proteins that protect them from degradation.276 
 
9. Biophysical properties 
 
9.1. Phase transition 
The involvement of IDRs in phase transitions is a surprising finding that provides a biophysical angle to the characterization 
of proteins that harbor disordered regions. Li and co-workers116 observed that interactions between recombinant proteins 
that contain multiple copies of an SH3 domain and IDRs with multiple instances of the proline-rich SH3 interaction motif 
(see section 3.1.) produced sharp liquid–liquid-demixing phase separations that result in micrometer-sized liquid protein-
based droplets (Figure 17A). The concentrations needed for the phase transition depend on the valency of the interacting 
elements. Importantly, experiments with the natural NCK–nephrin–N-WASP (neuronal Wiskott–Aldrich syndrome protein) 
complex, which contains multiple copies of the same SH3 interaction partners, showed the formation of similar dynamic 
droplets that lead to a significant increase in the activity of the actin nucleation factor Arp2/3.116 The formation of the 
droplets is controlled by the degree of phosphorylation of one of the interaction partners, which potentially explains how the 
phase transition is regulated in the cell. 
 
A related phenomenon occurs with RNA-binding proteins that contain IDRs with low sequence complexity, which have 
been associated with the regulated formation of cellular RNA granules.277 Various types of cellular RNA granules are used 
to modulate the fate of specific mRNAs, but their assembly mechanism has remained a mystery. Kato and co-workers278 
reconstituted granule-like RNA assemblies in vitro by exploiting low complexity IDRs. They demonstrated that the low-
complexity IDRs of certain RNA-binding proteins were necessary for the formation of granule-like assemblies and that high 
concentrations of these regions lead to a reversible phase transition with a highly dynamic hydrogel state (Figure 17B). 
Interestingly, hydrogels formed by the low-complexity IDR of one purified member of the granules are capable of binding 
IDRs of other members and thereby enable the assembly of heterogenous macromolecular structures.278 Overall, these 
findings indicate that the biophysical properties of certain IDRs (such as those that contain specific low-complexity regions 
or linear motifs) enable phase transitions that are likely to be exploited in various macromolecular assemblies and could 
function to bridge the length scale of proteins with that of organelles.279 
 
10. Discussion 
In order to get closer to full understanding of living cells, we need to know the function of each of their elements. The 
human genome project and the many sequencing projects since have helped reveal the number and make-up of the genes. 
Experimental research focused on understanding how individual proteins work on the molecular level has enabled enormous 
progress in our understanding of the workings of proteins in general and of the systems they work in. However, the majority 
of studies investigate a minority of individual proteins, which are interesting for a variety of reasons, such as their relevance 
for disease or because they are classical study objects. Thus, still many genes and the proteins they encode have not been 
studied and have unknown function. 
 
Many of the functionally uncharacterized proteins will be similar to already characterized ones.8-10 This notion forms the 
basis for computational methods that aim to improve annotation coverage by predicting the function of novel and undefined 
proteins based on information from better-studied proteins. Databases such as Pfam22 and SCOP24 attest to the success of 
these approaches. However, existing methods are focused primarily on sequences that give rise to well-folded protein 
structures and domains. As a result, it is much harder to gain insight into function of intrinsically disordered proteins (IDPs) 
and regions (IDRs), despite the increasing evidence of their prevalence and importance for protein functionality (Figure 
1).49 Many important disease proteins such as p53, Myc, α-synuclein and BRCA1 are highly disordered, underscoring the 
importance of disordered regions for understanding the molecular basis of human diseases.223,238 
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In this review, we have assembled an overview of the major approaches used to classify and categorize IDPs and IDRs 
(Table 1). These classification schemes help us understand how disordered protein functionality is defined and could be 
used to enhance function prediction for disordered protein regions. In these final sections we discuss the resources that are 
currently available to gain insight into IDR function, we address potential areas of improvement of the current approaches, 
and we speculate how combinations of multiple existing classifications could achieve high quality function prediction for 
IDRs. Finally, we suggest areas where increased efforts are likely to advance our understanding of the functions of 
structural disorder in proteins. 
 
10.1. Current methods for function prediction of IDRs and IDPs 
What methods and resources can a researcher use to gain insight into the functions of the disordered regions in a protein? 
Current approaches are mainly based on the presence of functional features such as short linear motifs (SLiMs), molecular 
recognition features (MoRFs), and intrinsically disordered domains (IDDs) (see section 3.). These aspects have the potential 
to shed light on which interaction partners an IDR may have and how many, as well as the mode of binding.  
 
10.1.1. Linear motif-based approaches 
Mapping of well-characterized linear motifs onto other protein sequences holds particular promise for discovering novel 
functionality. For example, proteomic characterization of the motif (RxxPDG) that recruits Tankyrase ADP-ribose 
polymerases has lead to the identification of novel Tankyrase substrates and explains the basis for mutations causing 
cherubism disease.280 Similarly, proteome-wide searches for the SxIP motif have resulted in the identification of previously 
uncharacterized microtubule plus-end tracking proteins.281 However, these types of individual studies require considerable 
resources. 
 
ScanSite,282 MiniMotif,106 and ELM105 are three major efforts aimed at the annotation of known instances of linear motifs, 
which are primarily found in IDRs, and their binding partners. ScanSite primarily identifies linear motifs that are likely to 
be phosphorylated and play key roles in signaling, such as SH2 and 14-3-3 motifs.282 Annotation of these sequence motifs is 
based on results from binding experiments with peptide libraries and phage display experiments. The MiniMotif106 and 
ELM105 databases aim to categorize linear motifs of all functions based on in-depth manual annotation of experimentally 
validated instances from the literature. Although these resources are excellent repositories of the functional sites that occur 
in IDRs, they do have certain shortcomings. For example, ScanSite has a limited scope in identifying phosphorylation sites 
and the annotations from MiniMotif are not publicly available. Though the ELM database is the most comprehensive 
database of functional features within IDRs, at present it does not have the resources to annotate all motifs in the literature; 
ELM contains almost 200 classes of linear motifs with over 2000 instances but more than 250 classes await annotation with 
this number constantly increasing. This has meant ELM is limited to annotating (a fraction) of the shorter motif classes and 
ignores the longer binding modules in disordered regions. 
 
Complementary to the annotation efforts, the linear motif resources employ prediction methods that map functionality onto 
regions of proteins with unknown function (i.e. unannotated regions). For example MiniMotif and ELM use regular 
expressions derived from experimentally validated and curated motif instances to search protein sequences. These searches 
bring up functional descriptions of sequence instances that match the regular expressions. A major problem in the 
computational detection of short motifs in particular is the high false positive rate, which means that it is very difficult for 
users to identify the instances that are most likely to be functional from the large total of mostly non-functional motif 
instances that result from these searches. To overcome this issue, both databases have developed additional methods to 
improve prediction accuracy that rely on the use of additional context information, such as accessibility (using structural 
models283 and predictions of intrinsic disorder71), evolutionary conservation,284,285 cell compartment (based on 
annotation),106,286 and protein-protein interactions.108,287,288 These efforts will need to be combined in the future with a 
clearer user interface so researchers can more easily identify the most relevant instances. 
 
De novo predictors make up the final category of motif resources. These predictors computationally identify putative 
uncharacterized motifs in protein sequences. There are two broad types: predictors that identify clusters of amino acids that 
are more conserved than surrounding residues (e.g. SLiMPrints289) or those that find short peptide patterns that are over-
represented in a set of sequences (e.g. DiliMot290 and SLiMFinder291). Although both approaches have been combined with 
the gene ontology terms of the identified proteins, further development is required to define potential functionality. 
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10.1.2. Molecular recognition feature-based approaches 
Two important methods exist for identifying novel binding modules in IDRs based on concept of molecular recognition 
features (MoRFs). MoRFpred predicts sequences that undergo disorder-to-order transitions of all types of MoRFs (α, β, coil 
and complex) using a combination of sequence alignment and machine learning predictions based on amino acid properties, 
predicted disorder, B-factors, and solvent accessibility.292 ANCHOR also predicts parts of disordered regions that are likely 
to fold upon binding with their interactors, but does so by identifying segments that cannot form enough favorable 
intrachain interactions to fold on their own and are likely to gain stabilizing energy by interacting with a globular protein 
partner.293,294  
 
An important shortcoming of the MoRF predictions is the difficultly in identifying which of the binding sites are relevant 
and what their functionality might be. This is primarily because the results are not linked to known MoRF instances with 
annotated functions, as is the case for linear motifs, and no clues are provided regarding the potential role of a binding site 
or its interacting partners. The IDEAL database295 collects verified elements in disordered regions that undergo coupled 
folding and binding upon interaction (Box 1). The careful annotation of well-described MoRFs in terms of their primary 
sequence propensities or interaction interfaces as well as their known binding partners, and integration of these annotations 
with MoRF predictions, would likely improve the use of these predictions for gaining insight into IDR functionality. 
 
10.1.3. Intrinsically disordered domain-based approaches 
Few attempts have systematically annotated protein domains that are largely made up of intrinsic disorder. To a certain 
extent, Pfam22 has developed models to predict intrinsically disordered domains (e.g. KID, WH2, RPEL and BH3 domains). 
However, this seems to be a simple consequence of the fact that these disordered domains can be described and detected by 
sequence profiles, rather than an effort directed at annotating long IDRs. ELM105 has also annotated a small number of long 
disordered domains, such as the WH2 motif, however the main focus of the database remains on short motifs. Finally, some 
of the IDRs that are present in annotated domains are in fact MoRFs or linear motifs, and linear motifs also frequently fold 
upon binding like MoRFs, underscoring the underlying connections between linear motifs, MoRFs, and IDDs as functional 
elements (see section 3.4.). 
 
10.1.4. Other approaches 
Only a few IDR classifications that are not based on linear motifs, MoRFs or IDDs have so far been exploited for function 
prediction. FFPred is a correlation-based approach that uses the length and position of IDRs along a sequence (see section 
5.5. and 5.6.), among other general protein features, to predict the function of the protein in terms of gene ontology 
categories (molecular activities and biological processes).176,296-298 The DisProt database of protein disorder166 (Box 1) lists 
functions of individual disordered regions, where know from experiments. The major limitation here being the small 
number of regions for which exact function has been characterized. 
 
10.2. Requirement for annotation 
Future effort in the classifications of IDRs and IDPs must be directed at annotation. Substantiating classes with more 
examples will lead to refinement of their function descriptions. For example, there are only a limited number of well-
characterized examples of proteins that contain the evolutionary flexible (e.g. RPA70 and Sky1) or constrained types of 
disorder (Rpl5 and Hsp90). The same is true for the different classes of dynamic disorder in protein complexes, though 
efforts are ongoing there.204 In terms of the functional features of IDRs, there is a need for annotating MoRFs and longer 
disordered binding regions as described in the previous section. Efforts directed at short linear motif have been very 
successful, but only a small fraction of the potentially thousands of motifs299 have been annotated. Pfam contains almost 
15,000 curated protein families,22 while ELM contains less than 200 motif classes,105 suggesting that significant numbers of 
functional features are still to be identified and further annotation is required. High-quality resources that collect all the 
experimentally validated functional regions of intrinsically disordered regions will provide a strong basis to map functional 
features onto novel proteins of unknown function. 
 
10.3. Integration of methods for finding IDR and IDP function 
The current methods for finding and classifying IDR and IDP function have been successful in the area of their focus. 
However, not all functional characteristics of disordered regions have been fully exploited, and neither is there a resource 
22 
that brings all of these aspects together. The combination of multiple categorizations and features of IDRs is likely to 
provide a better understanding of the functionalities encoded in these regions. 
 
A comprehensive IDR function resource should have several aspects. It starts with a reliable consensus disorder prediction 
for the protein sequence of interest, such as available in the D2P2 database (Box 1).48 Functional features, such as SLiMs 
(see section 3.1.), MoRFs (see section 3.2.), and disordered domains (see section 3.3.) can then be mapped on every 
disordered part of the protein. The disorder profile allows for the identification of individual IDRs in the protein, as well as 
the calculation of disorder properties of the whole protein, such as which disorder predictors support which IDRs (see 
section 5.2.), the overall degree of disorder (see section 5.4.), the length of the individual disordered regions (see section 
5.5.), or the amount of disorder at the termini (see section 5.6.). These can be used to assign general function to the proteins, 
such as gene ontology terms that correlate with these properties. Patterns in primary amino acid sequence could reveal 
additional function. For example, the presence of tandem repeats (see section 5.7. and 7.3.) may point at involvement in 
certain processes. The overall sequence composition and the distribution of charges (see section 5.1.) could indicate 
conformational properties such as the degree of compaction of the chain (see section 4.) and the combination of primary 
sequence complexity and disorder propensity could suggest function as well (see section 5.3.). 
 
Integration of other types of information will determine what classifications can additionally be used. Addition of domain 
information, such as Pfam, can provide insight into the role of disordered segments that are commonly associated with 
specific structured domains (see section 3.3.). Protein-protein interactions and structures of protein complexes could 
indicate interacting partners of IDR binding elements and the mode of interaction (see section 6.). Information about 
sequence conservation (see section 7.1.) is another important aspect and could provide clues about evolutionary constrained 
or flexible types of disorder, which are implicated in different types of functioning. Knowledge on the origin of a disordered 
region in evolution or the species containing the protein sequence of interest suggests possible roles as well (see section 
7.2.). Furthermore, data describing regulatory properties like gene expression levels (see section 8.1.), alternative splicing 
(see section 8.2.) and degradation kinetics (see section 8.3.) could implicate IDRs in regulating protein availability and may 
suggest or reject roles as for example interactions hubs. Finally, biophysical properties of the protein, such as the potential 
of multivalent elements to undergo phase transitions (see section 9.1.), may suggest involvement in spatial-temporal 
localization of cellular components for example through the construction of subcellular granules. 
 
The hypothetical resource might be able to suggest function for some of the following examples, although it is clear that in 
other cases the biology will be too complicated and the outlook of function prediction as described here will be unrealistic. 
Therefore, these examples should at this point be considered as speculative. A long (more than 30 residues) IDR that shows 
signs of evolutionary flexible disorder and contains no short motifs or other predicted binding regions could be a flexible 
linker between domains or an entropic chain. A region containing a PxxPx[KR] motif flanked by evolutionary flexible 
disorder that is likely to retain an open conformation in the unbound form (based on the primary sequence) probably binds a 
class II SH3 domain, and might be involved in transcription processes if the IDR constitutes the C-terminus of a protein 
with an otherwise small degree of disorder. Long IDRs that are encoded by alternatively spliced exons and have several 
non-overlapping functional motifs and MoRFs might be part of signaling hubs or assemble multiprotein complexes, the type 
of which might be inferred from the combination of binding sites present. A constitutively expressed, largely disordered 
IDP with an amino acid composition promoting intrinsic coil conformations and conservation of both primary and disorder 
sequence is likely to be a ribosomal protein.  
 
It is clear that some classifications will provide more useful and direct information about function than others. Some 
classifications have been proposed to contrast IDPs with structured proteins, which does not necessarily make them useful 
for a detailed description of disorder function per se. Others have limited use for prediction because they are conceptual 
only, or because of overlap in the properties they describe with other schemes. Moreover, not all approaches can 
realistically be incorporated in a tool. Binding functionality and sequence-based predictions will generally be possible, but 
predictions based on other types of data may be harder. For example, assignment of evolutionary constrained or flexible 
disorder requires automatic alignment of primary and disorder sequences, while gene expression subtypes can be derived 
from the wealth of microarray and RNA sequencing data. Various types of information are already brought together in the 
D2P2 database,48 which contains information on disordered regions, MoRFs, PTM sites, and structured domains, and in 
ELM,105 which shows information on linear motifs, disorder, phosphorylation, domains, protein-protein interactions and 
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secondary structure. Further extension of resources like these, with information on both structured and disordered regions, 
holds great promise towards creating comprehensive overviews of the functional elements and properties of a protein. 
 
10.4. Future directions 
A major area of improvement in the description of disordered protein regions pertains to their dynamic behavior. IDRs 
fluctuate rapidly over an ensemble of heterogeneous conformations (see section 4.1.), the individual energy levels and 
propensities of which are determined by the primary sequence. The relationship between sequence and ensemble is 
important because it describes what part of the time the chain is in a compact state, and what part of the time it is more 
accessible (see section 4. and 5.1.). Knowledge about these structural subtypes and about how sequence contexts and 
chemical modifications of the chain (e.g. by PTMs) modulate the ensemble is vital for correct description of IDR behavior 
and has direct implications for the functional roles such regions can have in the cell. 
 
Existing methods are not designed to take structural dynamics into account. For example, current disorder prediction 
technology is successful at distinguishing sequence stretches that are likely to be disordered versus those that are likely to be 
part of autonomously folded domains, resulting in a binary verdict (disordered versus structured) within a certain confidence 
limit. Detailed prediction of conformational subtypes requires a more sophisticated description of disorder. For example, 
high-throughput atomistic simulations of sequence ensembles can provide information about the degree of conformational 
heterogeneity,300 which can be quantified by various parameters, such as an information theory measure301 or an order-
parameter-like measure.302 One could imagine a multiple-component scheme describing structural and dynamic 
characteristics that would assign for example residues in a random coil small values for the fractional population of 
secondary structure, a large value for spatial fluctuations, a fast interconversion rate, and large values for structural 
heterogeneity. Conversely, molten globule residues would be assigned a relatively large value for the fractional population 
of secondary structure, a smaller value for spatial fluctuations and structural heterogeneity, and a slower interconversion 
rate. There is considerable room for growth at the interface between atomistic simulations, physical theories, machine 
learning methods, and experiments, to enable the unmasking of the connection between disorder dynamics and molecular 
and system level functions of IDRs and IDPs. 
 
Full understanding of the cellular function of IDPs will also require knowledge of their abundance, their interactions, and 
their physical state in the physiological context. Are IDPs always bound to target proteins, are they chaperoned, or are there 
pools of unbound IDPs? Answers to these questions will vary amongst different IDPs, but the discovery of features that can 
help classify and categorize them in terms of their cellular status will lead to more insights into their function. For example, 
entropic chains may mostly be disordered even in the cell, whereas effectors and assemblers may mostly be associated with 
other proteins in folded conformations and exchange binding partners by competition rather than by dissociation to the free, 
disordered state. Scavengers likely populate both disordered and ordered states, depending on whether or not their ligand is 
bound. Thus, investigations of the in-cell status of IDPs will be crucial towards understanding their biological roles. 
 
11. Conclusion 
The functional versatility of intrinsically disordered regions in proteins is remarkable. Our hope is that the overview of 
different groups, categories, types, and classes of IDRs in this review provides a basis for understanding how this functional 
versatility is achieved and that it offers novel ways of combining this knowledge to gain insight into the function of 
uncharacterized proteins. 
 
Finally, we would like to stress that it is not all about intrinsic disorder. This review has focused on classifications for 
intrinsically disordered regions and proteins, because function annotation for these regions is lagging behind annotation of 
structured regions. However, proteins are modular303 and their functional regions can be structured or disordered, or 
somewhere in between. The synergy between these fundamental building blocks of proteins leads to combinatorial diversity 
of functions and understanding how they work together will be key to understanding the full extent of protein function. 
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Boxes 
 
Box 1: Databases of intrinsically disordered regions and proteins 
Several resources exist that collect experimental or computational information on disordered regions in proteins. The 
Database of Protein Disorder (DisProt, http://www.disprot.org/) was developed to facilitate research on protein disorder by 
collecting and organizing the rapidly increasing knowledge about the experimental characterization and the functionalities 
of IDRs and IDPs.166,304 For each disordered protein (i.e. a protein that contains at least one experimentally determined 
disordered region), the database includes the name of the protein, various aliases, accession codes, amino acid sequence, 
location of the disordered region(s), and methods used for disorder characterization. Additionally, where known, entries list 
the biological function of each disordered region and how each region of disorder is used for function. The data on 
disordered regions in DisProt often serves as a standard for the training and verification of disorder predictors. As of release 
6.02 (May 24, 2013) DisProt contains 694 intrinsically disordered protein entries and 1539 disordered regions. 
 
The IDEAL database (Intrinsically Disordered proteins with Extensive Annotations and 
Literature, http://www.ideal.force.cs.is.nagoya-u.ac.jp/IDEAL/) also collects annotations of experimentally verified 
intrinsically disordered proteins.295 This database focuses on the functional regions within IDRs, such as those that interact 
with other proteins and post-translational modification sites. IDEAL collects verified IDRs that undergo coupled folding 
and binding upon interaction (regions for which there is evidence for both a disordered isolated state and an ordered bound 
state), such as MoRFs and certain linear motifs (see section 3.). It also suggests putative sequences for which there is only 
evidence of an ordered bound state, but that are thought to undergo induced folding based on circumstantial evidence, such 
as the presence of a verified folding-upon-binding element in a homolog. The version of 30 August 2013 contains 340 
proteins with annotated disordered regions of which 148 contain verified or putative elements that undergo folding upon 
binding. 
 
Another database that collects experimental data and predictions of disorder in proteins is MobiDB 
(http://mobidb.bio.unipd.it/).305 MobiDB collects experimental data from DisProt,166 IDEAL,295 and the Protein Data 
Bank125 (missing residues in crystal structures and structurally mobile regions in NMR ensembles). Prediction data comes 
from three different methods. The total of disorder information is summarized in a weighted consensus. Version 1.2.1 
(August 28, 2012) contains 26,933 proteins for which there is experimental data on the presence or absence of disorder and 
4,662,776 proteins from 297 proteomes for which there are disorder predictions. 
 
Finally, the Database of Disordered Protein Prediction (D2P2, http://d2p2.pro) stores disorder predictions made by nine 
different predictors for a large library of proteins from completely sequenced genomes.48 Alongside the disorder predictions, 
it contains information on MoRFs (ANCHOR293), PTM sites (PhosphoSitePlus306), and domains (SCOP24 and Pfam22). As 
of September 2013, D2P2 contains disorder predictions for 10,429,761 sequences in 1,765 genomes from 1,256 distinct 
species.  
 
Box 2: Experimental detection of disordered regions 
IDRs have been studied using a variety of experimental techniques, including NMR, X-ray, SAXS, proteomics, and 
protease susceptibility essays. NMR spectroscopy is the key method to characterize protein disorder, owing to its ability to 
provide residue-level information on protein structure and dynamics in solution.307 Many aspects of disorder biology can be 
detected directly using NMR, including local disorder, folding upon binding, and disorder in complex. In contrast to NMR 
methods, detection of disorder using X-ray crystallography techniques is mainly indirect as it relies on missing electron 
density.32 Another powerful method for detecting and characterizing IDPs is small-angle X-ray scattering (SAXS), which 
assesses protein dimensions and shape by measuring the scattered X-ray intensity caused by a sample. SAXS can be used to 
determine hydrodynamic parameters and the degree of globularity of a protein, which are good indicators to determine 
whether a protein is compact or unfolded.146 High-throughput proteomic approaches are also used for identification of IDPs. 
These techniques enrich cellular extracts for disordered proteins, and then separate structured from disordered proteins, 
followed by identification (e.g. by mass spectrometry). For example, heat treatment enriches cell extracts for IDPs and 
depletes for proteins containing folded domains.174 IDPs can also be identified on the basis of their susceptibility to 
degradation by the 20S proteasome under conditions in which structured proteins are resistant (see section 8.3.).274 The 
degradation assays can also be used to identify binding partners of IDPs that provide protection against degradation. The 
DisProt, IDEAL and MobiDB databases collect experimentally verified disordered regions and proteins (Box 1). 
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Box 3: Evolution of disordered regions 
IDRs generally evolve faster than their structured counterparts.50-55,92 Direct comparison between the rates of evolution of 
structured and disordered regions in 26 protein families has shown that not all disordered regions evolve faster than 
structured regions; some evolve more slowly, and in other cases they evolve at roughly the same rate.50 In order to get more 
insight into the evolution of disordered regions and proteins, we predicted intrinsic disorder in the human proteome using 
MULTICOM-REFINE.308 We integrated the disorder status of the protein residues with their evolutionary rates across 
multiple sequence alignments of homologous proteins from 53 mostly vertebrate species in Ensembl Compara1, calculated 
using the Rate4Site program.309 As observed previously,310 protein residues that are predicted to be disordered generally 
evolve more quickly (i.e. have much higher evolutionary rates) than those in structured regions (Figure Box 3, P value < 
10-15, Mann-Whitney U test). However, the distributions of evolutionary rates for disordered and structured residues are 
wide and overlap (Figure Box 3). Thus, although IDRs generally evolve more quickly, some disordered residues are 
conserved. In line with this, it has been shown that particular residue types, such as leucine, tyrosine, tryptophan, and 
proline, are more conserved in IDRs than other residue types.52 Conserved residues and elements in IDRs are potentially 
important for function and might for example be part of protein-protein interaction interfaces and peptide motifs (see 
section 7.1.). 
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Tables 
 
Table 1: Classifications of Intrinsically Disordered Regions and Proteins. 
 
Basis for classification Classes Description Examples 
Function  33,38,56,57 • Entropic 
chains 
IDRs carrying out functions that benefit directly from their conformational disorder, e.g. 
flexible linkers and spacers. 
MAP2 projection domain, titin 
PEVK domain, RPA70 
• Display sites Flexibility of IDRs facilitates exposure of motifs and easy access for proteins that 
introduce and read PTMs. 
p53, histone tails, p27, CREB 
kinase-inducible domain 
• Chaperones Their binding properties (many different partners, quick interactions, and folding upon 
binding) make IDPs suitable for chaperone functions. 
hnRNP A1, GroEL, Hsp33 
• Effectors Folding upon binding mechanics allow effectors to modify the activity of their partner 
proteins. 
p21, p27, calpastatin, WASP 
GTPase-binding domain 
• Assemblers Assembling IDRs have large binding interfaces that scaffold multiple binding partners 
and promote the formation of higher-order protein complexes. 
ribosomal proteins L7, L12, Tcf 
3/4, CREB transactivator domain, 
Axin 
• Scavengers Disordered scavengers store and neutralize small ligands. chromogranin A, casein, pro-rich 
glycoproteins 
Functional 
features 
Linear motifs 
46,105 
• Structural 
modification 
Sites of conformational alteration of a peptide backbone. peptidylprolyl cis-trans isomerase 
Pin1 sites 
• Proteolytic 
cleavage 
Sites of post-translational processing events or proteolytic cleavage scission sites. Caspase-3/-7, Seperase, Taspase1 
scission sites 
• PTM 
removal/ 
addition 
Specific binding sequences that recruit enzymes catalyzing PTM moiety addition or 
removal. 
cyclin-dependent kinase 
phosphorylation site, 
SUMOylation site, N-
glycosylation site 
• Complex 
promoting 
Motifs that mediate protein-protein interactions important for complex formation often 
associated with signal transduction. 
 
proline-rich SH3-binding motif, 
cyclin box, pY SH2-binding 
motif, PDZ-binding motif 
• Docking Motifs that increase the specificity and efficiency of modification events by providing an 
additional binding surface. 
KEN box degron, MAPK 
docking sites 
• Targeting or 
trafficking 
Signal sites that localize proteins within particular subcellular organelles or act to traffic 
proteins. 
nuclear localization signal, 
clathrin box motif, endocytosis 
adaptor trafficking motifs 
Molecular recognition 
features (MoRFs) 
101 
• Alpha Disordered motifs that form α-helices upon target binding.  p53 ~ Mdm2, p53 ~ RPA70, p53 
~ S100B(ββ), RNase E ~ enolase, 
inhibitor IA3 ~ proteinase A 
• Beta Disordered motifs that form β-strands upon target binding. Rnase E ~ polynucleotide 
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phosphorylase, Grim ~ DIAP1, 
pVIc ~ Adenovirus 2 proteinase 
• Iota Disordered motifs that form irregular secondary structure upon target binding. p53 ~ Cdk2-cyclin A, 
Amphiphysin ~ α-adaptin C 
• Complex Disordered motifs that contain combinations of different types of secondary structure 
upon target binding. 
Amyloid β A4 ~ X11, WASP ~ 
Cdc42 
Intrinsically 
disordered domains 
(IDDs) 136,137 
 Some proteins domains identified using sequence-based approaches are fully or largely 
disordered. 
WH2, RPEL, BH3, KID domains 
Co-occurrence of 
protein domains with 
disordered regions 
139,140 
 Particular disordered regions frequently co-occur in the same sequence with specific 
protein domains. 
 
Structure Protein quartet 
32,34,144 
• Intrinsic coil Flexible regions of extended conformation with hardly any secondary structure. High net 
charge differentiates these from disordered globules. 
ribosomal proteins L22, L27, 
30S, S19, prothymosin α 
• Pre-molten 
globule 
Disordered protein regions with residual secondary structure, often poised for folding 
upon binding events. Lower net charge makes them more compact than coils. 
Max, ribosomal proteins S12, 
S18, L23, L32, calsequestrin 
• Molten 
globule 
Globally collapsed conformation with regions of fluctuating secondary structure. nuclear coactivator binding 
domain of CREB binding protein 
• Folded Structured proteins with a defined three-dimensional structure. most enzymes, transmembrane 
domains, hemoglobin, actin, etc. 
Sequence Sequence-ensemble 
relationships 144,167 
• Polar tracts Sequence stretches enriched in polar amino acids often form globules that are generally 
devoid of significant secondary structure preferences. 
Asn-, and Gly-rich sequences, 
Gln-rich linkers in transcription 
factors and RNA-binding 
proteins 
• Polyelectroly
tes 
Amino acid compositions biased toward charged residues of one type; strong 
polyelectrolytes (high net charge) form expanded coils. 
Arg-rich protamines, Glu/Asp-
rich prothymosin α 
• Polyampholy
tes 
Sequences with roughly equal numbers of positive and negative charges. Conformations 
of polyampholytes are governed by the linear distribution of oppositely charged residues, 
with segregation of opposite charges leading to globules, while well-mixed charged 
sequences adopt random-coil or globular conformations, depending on the total charge. 
RNA chaperones, splicing 
factors, titin PEVK domain, yeast 
prion Sup35 
Prediction flavors 
170 
• V Predicted best by the VL-2V predictor, for which the hydrophobic amino acids are the 
most influential attributes. 
E.coli ribosomal proteins 
• C VL-2C is the best predictor for flavor C, which has more histidine, methionine and 
alanine residues than the other flavors. 
poly- and oligosaccharide 
binding domains 
• S Flavor with less histidine than the others, best predicted by predictor VL-2S, which has a 
measure of sequence complexity as the most important attribute.  
proteins that facilitate binding 
and interaction 
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Disorder-complexity 
171 
 IDPs from different function classes show distinct disorder-complexity distributions. Disordered linkers of structured 
domains populate compact and 
disordered DC regions. 
Overall degree of 
disorder 
35,50,67,139,173,174 
• Fraction Categorization of proteins based on the fraction of residues predicted to be disordered. 0-10/10-30/30-100% disorder 
• Overall 
score 
Overall disorder scores for the whole protein. residue score average >0.5 
• Continuous 
stretches 
Presence or absence of continuous stretches of disordered residues. typically >30 residues 
Length of disordered 
regions 176 
• >500 
residues 
Proteins that contain disordered regions of different lengths are enriched for different 
types of functions. 
transcription 
• 300-500 
residues 
kinase and phosphatase functions 
 
• <50 residues (metal) ion binding, ion channels, 
GTPase regulatory activity 
Position of disordered 
regions 176 
• N-terminal 
Proteins that contain disordered regions at different locations in the sequence are enriched 
for different types of functions. 
DNA-binding, ion channel 
• Internal transcription regulator, DNA-
binding 
• C-terminal transcription repressor/activator, 
ion channel 
Tandem repeats 
180,181 
 
• Q/N Glutamine- and asparagine-rich proteins regions are both important for normal cellular 
function and prone to harmful aggregation. 
huntingtin, Sup35p, Ure2p, Ccr4, 
Pop2 
• S/R Tandem repeats composed of arginine and serine residues are phosphorylated and 
disordered, and play a role in spliceosome assembly. 
ASF/SF2, SRp75 
• K/A/P Tandem repeats composed of lysine, alanine and proline function in binding nucleosome 
linker DNA. 
histone H1 
• F/G Disordered domains with phenylalanine-glycine repeats influence NPC gating behavior. Nucleoporins 
• Etc.   
Protein 
interactions 
Fuzzy complexes by 
topology 202 
• Polymorphic A form of static disorder, with alternative bound conformations serving distinct functions 
by having different effects on the binding partner. 
β-catenin ~ Tcf4, NLS ~ 
importin-α, actin ~ WH2 domain 
• Clamp Complex formation through folding upon binding of two disordered protein segments, 
connected by a linker that remains disordered. 
Ste5 ~ Fus3, Myosin VI ~ actin 
filament, Oct-1 ~ DNA 
• Flanking Complex formation through folding upon binding of a central disordered protein segment, 
flanked by two regions that remain disordered. 
SF1 splicing factor ~ U2AF, 
proline-rich peptides ~ SH3 
domains, p27Kip1 ~ cyclin-Cdk2 
• Random Disordered regions that remain highly dynamic even in the bound state. elastin self-assembly, Sic1 ~ 
Cdc4 
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Fuzzy complexes by 
mechanism 204,211 
• Conformatio
nal selection 
The fuzzy region facilitates the formation of the binding competent form by shifting the 
conformational equilibrium. 
Max ~ DNA, MeCP2 ~ DNA 
• Flexibility 
modulation 
The fuzzy region modulates the flexibility of the binding interface and changes binding 
entropy. 
Ets-1 ~ DNA, SSB ~ DNA 
• Competitive 
binding 
The fuzzy region serves as an intramolecular competitive partner for the binding surface. HMGB1 ~ DNA, RNase1 ~ 
RNase inhibitor 
• Tethering The fuzzy region increases the local concentration of a weak-affinity binding domain near 
the target, or anchors it via transient interactions. 
RPA ~ DNA, UPF1 ~ UPF2, PC4 
~ VP16 
Binding plasticity 
216 
• Static Mono-/polyvalent complexes, chameleons, penetrators, huggers.  
• Coiled-coil 
based 
Intertwined strings, long cylindrical containers, connectors, armature, tweezers and 
forceps, grabbers, tentacles, pullers, stackers. 
 
• Dynamic Cloud contacts and protein interaction ensembles.  
Evolution Sequence conservation 
53 
• Flexible Regions that require the property of disorder for functionality regardless of the exact 
sequence. 
signaling and regulatory proteins 
(Sky1, Bur1) 
• Constrained Regions of conserved disorder with also highly conserved amino acid sequences. ribosomal proteins (Rpl5), 
protein chaperones (Hsp90) 
• Non-
conserved 
No conservation of the disorder, nor of the underlying sequence; no clear functional 
hallmarks. 
yeast Ty1 retrotransposon 
domains A and B 
Conservation of amino 
acid composition 219 
• HR IDRs with high residue conservation. transcription regulation and DNA 
binding 
• LRHT IDRs with low residue conservation but high conservation of the amino acid composition 
of the region. 
ATPase and nuclease activities 
• LRLT IDRs with neither conservation of sequence nor conservation of amino acid composition. (metal) ion binding proteins 
Lineage and species 
specificity 137 
• Prokaryotes 
Species from different kingdoms of life seem to use disorder for different types of 
functions. 
longer lasting interactions 
involved in complex formation 
• Eukaryotes 
and viruses 
transient interactions in signaling 
and regulation 
History and 
mechanism of repeat 
evolution 60 
• Type I Repeats that showed no function diversification after expansion. titin PEVK domain, salivary 
proline-rich proteins 
• Type II Repeats that acquired diverse functions through mutation or differential location within 
the sequence. 
RNA polymerase II (CTD) 
• Type III Repeats that gained new functions as a consequence of their expansion. prion protein octarepeats 
Regulation Expression patterns 
173 
• Constitutive IDPs encoded by constitutively highly expressed transcripts are almost entirely 
disordered and often ribosomal proteins. 
ribosomal L proteins 
• High IDP encoding transcripts showing high expression levels in most tissues and little tissue protease inhibitors, splicing 
factors, complex assemblers 
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specificity. 
• Medium These IDP encoding transcripts are expressed at medium levels, with some tissue-
specificity. 
DNA binding, transcription 
regulation 
• Tissue-
specific 
IDP encoding transcripts with highly tissue-specific expression. cell organization regulators, 
complex disassemblers 
• Low or 
transient 
IDP encoding transcripts that are present in undetectable amounts; more than half of 
analyzed IDPs. 
variety of functions 
Alternative splicing 
246,247,251,254,255 
 Regulation and evolutionary patterns of inclusion and exclusion of IDR-encoding exons 
can give insights into whether the encoded IDR functions in protein regulation and 
interactions. 
a tissue-specific peptide with a 
phosphosite in the TJP1 protein 
in mouse, a Mammalian-specific 
peptide in the PTB1 splicing 
regulator 
Degradation kinetics 
256-258,260,262,263 
• Degradation 
accelerators 
IDRs that can influence and accelerate proteasomal degradation of the protein they are 
part of. 
 
• Others IDRs that have no influence on protein half-life or increase it, e.g. because of sequence 
composition that is incompatible with the proteasomal mechanism of degradation. 
 
Biophysical 
properties 
Phase transition 116,278  Certain IDRs (such as those that contain specific low-complexity regions or interaction 
motifs) can undergo phase transitions like the formation of protein-based droplets or 
hydrogels. 
Multivalent SH3-binding motifs 
in phase separation, granule-like 
assemblies of RNA-binding 
proteins containing low-
complexity IDRs 
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Figure legends 
 
Figure 1: Structured domains and Intrinsically Disordered Regions (IDRs) are two fundamental classes of functional 
building blocks of proteins. The synergy between disordered regions and structured domains increases the functional 
versatility of proteins. 
 
Figure 2: The number of protein-coding genes in the human genome with various amounts of disorder. Histograms of 
the numbers of human genes with annotation (A) and without annotation (B), grouped by the percentage of disordered 
residues. (C) A comparison of the fraction of annotated and unannotated human genes with different amounts of disorder. 
Residues in each protein are defined as disordered when there is a consensus between >75% of the predictors in the D2P2 
database48 at that position. The set of human genes was taken from ENSEMBL release 63,1 and the representative protein 
coded for by the longest transcript was used in each case. The annotation was taken from the description field with ‘open 
reading frame’, ‘hypothetical’, ‘uncharacterized’ and ‘putative protein’ treated as no annotation. 
 
Figure 3: The fraction of disordered residues located in domains in human protein-coding genes: (A) residues inside 
(left) and outside (right) of SCOP domains,24 and (B) residues inside (left) and outside (right) of Pfam domains.22 The 
SCOP domains in human proteins are defined by the SUPERFAMILY database.10 Disordered residues were taken from the 
D2P2 database48 (when there is a consensus between >75% of the disorder predictors). The set of human genes was taken 
from ENSEMBL release 63.1 
 
Figure 4: Functional classification scheme of IDRs. The function of disordered regions can stem directly from their 
highly flexible nature, when they fulfill entropic chain functions (such as linkers and spacers, indicated in dark-tone red), or 
from their ability to bind to partner molecules (proteins, other macromolecules, or small molecules). In the latter case, they 
bind either transiently as display sites of post-translational modifications or as chaperones (indicated in green), or they bind 
permanently as effectors, assemblers or scavengers (indicated in dark-tone blue). More extensive descriptions and examples 
are found in the main text. Adapted from Tompa (2005)57. 
 
Figure 5: Functional classification of IDRs according to their interaction features. (A) The flexibility of IDRs 
facilitates access to enzymes that catalyze post-translational modifications and effectors that bind these PTMs. This permits 
combinatorial regulation and re-use of the same components in multiple biological processes. (B) The availability of 
molecular recognition features and linear motifs within the IDRs enable the fishing for (‘fly-casting’) and gathering of 
different partners. (C) Conformational variability enables a nearly perfect molding to fit the binding interfaces of very 
diverse interaction partners. Context-dependent folding of an IDR can activate signaling processes in one case or inhibit 
them in another, resulting in completely different outcomes. 
 
Figure 6: Functional classification of linear motifs. Linear motifs can be divided into two major families, which each 
have three further subgroups. The modification class motifs all act as recognition sites for enzyme active sites, whereas the 
ligand class motifs are always recognized by the binding surface of a protein partner. More detailed classification beyond 
the graph shown here is possible. For example, an important subgroup of docking motifs are the degrons, which regulate 
protein stability by recruiting members of the ubiquitin-proteasome system. In the regular expressions, x corresponds to any 
amino acid, while other letters represent single letter codes of amino acids; letters within square brackets mean either 
residue is allowed in that position. 
 
Figure 7: Classification of molecular recognition features (MoRFs) based on the secondary structure of the bound 
state. MoRFs (red ribbons) undergo disorder-to-order transition upon binding their partners (blue surfaces). (A) α-
MoRF. BH3 domain of BAD (MoRF) bound to bcl-xl (partner) (PDB ID: 1G5J). (B) β-MoRF. Inhibitor of apoptosis 
protein DIAP1 (partner) bound to N-terminus of cell death protein GRIM (MoRF) (PDB ID: 1JD5). (C) ι -MoRF. AP-2 
(partner) bound to the recognition motif of amphiphysin (MoRF) (PDB ID: 1KY7). (D) complex-MoRF. Phosphotyrosine-
binding domain (PTB) of the X11 protein (partner) bound to amyloid beta A4 protein (MoRF) (PDB ID: 1X11). Note that 
the PTB domain of X11 actually binds unphosphorylated peptides and is a PTB by sequence similarity. Reproduced from 
Vacic et al. (2007)102. (E) Promiscuity of disorder-controlled interactions illustrated by the p53 interaction network. A 
structure versus disorder prediction on the p53 amino acid sequence is shown in the center of the figure (up = disorder, 
down = order) along with the structures of various regions of p53 bound to fourteen different partners. The predictions for a 
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central region of structure and disordered amino and carbonyl termini have been confirmed experimentally for p53. The 
various regions of p53 are color coded to show their structures in the complex and to map the binding segments to the 
amino acid sequence. Starting with the p53-DNA complex (top, left, magenta protein, blue DNA), and moving in a 
clockwise direction, the Protein Data Bank125 IDs and partner names are given as follows for the fourteen complexes: (1tsr – 
DNA), (1gzh – 53BP1), (1q2d – gcn5), (3sak – p53 (tetramerization domain)), (1xqh – set9), (1h26 – cyclinA), (1ma3 – 
sirtuin), (1jsp – CBP bromo domain), (1dt7 – s100ββ), (2h1l – sv40 Large T antigen), (1ycs – 53BP2), (2gs0 – PH), (1ycr – 
MDM2), and (2b3g – RPA70). Reproduced from Uversky and Dunker (2010)39. 
 
Figure 8: Schematic representation of the continuum model of protein structure. The color gradient represents a 
continuum of conformational states ranging from highly dynamic, expanded conformational ensembles (red) to compact, 
dynamically restricted, fully folded globular states (blue). Dynamically disordered states are represented by heavy lines, 
stably folded structures as cartoons. A characteristic of IDPs is that they rapidly interconvert between multiple states in the 
dynamic conformational ensemble. In the continuum model, the proteome would populate the entire spectrum of dynamics, 
disorder, and folded structure depicted. 
 
Figure 9: The protein quartet model of protein conformational states. In accordance with this model, protein function 
arises from four types of conformations of the polypeptide chain (ordered forms, molten globules, pre-molten globules, and 
random coils) and transitions between any of these states. 
 
Figure 10: Original144 and modified167 diagram-of-states to classify predicted conformational properties of IDPs (and 
IDRs modeled as IDPs). (A) The original diagram predicts that sequences with a net charge per residue above 0.25 will be 
swollen coils. The three axes denote the fraction of positively charged residues, f+, the fraction of negatively charged 
residues, f–, and the hydropathy. All three parameters are calculated from the amino acid composition. Green dots 
correspond to 364 curated disordered sequences extracted from the DisProt database.166 These sequences have hydropathy 
values that designate them as being disordered, i.e. they lie in the bottom portion of the pyramid by definition. Additional 
filters were used for chain length (more than 30 residues) and the fraction of proline residues (fpro < 0.3). 97% of sequences 
used in this annotation have a net charge per residue of less than 0.26 and are thus predicted to be globule formers.167 (B) 
Modified diagram-of-states from panel (A) with a focus only on the bottom portion of the pyramid (i.e. stipulating that the 
hydropathy is low enough to be ignored).167 The polyampholytic contribution expands the space encompassed by non-
globule-formers by subdividing the disordered globules space in panel (A) into three distinct regions of which sequences in 
regions 2 and 3 actually may not form globules. In these polyampholytic regions, one has to account for the total charge, in 
terms of the fraction of charged residues (FCR), as well as the net charge per residue (NCPR) as opposed to NCPR alone. 
Conformations in regions 2 and 3 are expected to be random-coil-like if oppositely charged residues are well mixed in the 
linear sequence. Otherwise, one can expect compact or semi-compact conformations. The classification scheme uses only 
the amino acid sequence as input. 
 
Figure 11: Classification of fuzzy complexes by topology (upper panel) and by mechanism (lower panel). Blue arrows 
indicate interactions between fuzzy disordered regions and structured molecules. Protein Data Bank125 identifiers for the 
structures are given in parentheses. Topological categories: (A) Polymorphic. The WH2 domain of cibulot interacts with 
actin in alternative locations: via an 18-residue segment (3u9z) or via only three residues (2ff3). The flanking regions 
remain dynamically disordered. (B) Clamp. The Oct-1 transcription factor has a bipartite DNA recognition motif. The two 
globular binding domains are connected by a 23 residue long disordered linker (1hf0), shortening of which reduces binding 
affinity. (C) Flanking. The p27Kip1 cell-cycle kinase inhibitor binds to the cyclin-Cdk2 complex (1jsu). The kinase binding 
site is flanked by a ~100 residue long disordered linker, which enables T187 at the C-terminus to be phosphorylated. (D) 
Random. UmuD2 is a dimer that is produced from UmuD by RecA-facilitated self-cleavage (1i4v). The resulting proteins 
exhibit a random coil signal in circular dichroism experiments at physiologically relevant concentrations. Mechanistic 
categories: (E) Conformational selection. The fuzzy N-terminal acidic tail of the Max transcription factor (1nkp) facilitates 
formation of the DNA binding helix (dark red) of the leucine zipper basic helix-loop-helix (bHLH) motif. (F) Flexibility 
modulation. The disordered serine/arginine-rich region of Ets-1 transcription factor (1mdm) changes DNA binding affinity 
by 100–1000-fold by modulating the flexibility of the binding segment via transient interactions. (G) Competitive binding. 
The acidic fuzzy C-terminal tail of high-mobility group protein B1 (2gzk) competes with DNA for the positively charged 
binding surfaces. (H) Tethering. The binding of the virion protein 16 activation domain to the human transcriptional 
coactivator positive cofactor 4 (2phe) is facilitated by acidic disordered regions, which anchor the binding segments. 
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Figure 12: A portrait gallery of disorder-based complexes. Illustrative examples of various interaction modes of 
intrinsically disordered proteins are shown. Protein Data Bank125 identifiers for the structures are given in parentheses. (A) 
MoRFs. Aa, α-MoRF, a complex between the botulinum neurotoxin (red helix) and its receptor (a blue cloud) (2NM1); Ab, 
ι-MoRF, a complex between an 18-mer cognate peptide derived from the α1 subunit of the nicotinic acetylcholine receptor 
from Torpedo californica (red helix) and α-cobratoxin (a blue cloud) (1LXH). (B) Wrappers. Ba, rat PP1 (blue cloud) 
complexed with mouse inhibitor-2 (red helices) (2O8A); Bb, a complex between the paired domain from the Drosophila 
paired (prd) protein and DNA (1PDN). (C). Penetrator. Ribosomal protein s12 embedded into the rRNA (1N34). (D). 
Huggers. Da, E. coli trp repressor dimer (1ZT9); Db, tetramerization domain of p53 (1PES); Dc, tetramerization domain of 
p73 (2WQI). (E) Intertwined strings. Ea, dimeric coiled coil, a basic coiled-coil protein from Eubacterium eligens ATCC 
27750 (3HNW); Eb, trimeric coiled coil, salmonella trimeric autotransporter adhesin, SadA (2WPQ); Ec, tetrameric coiled 
coil, the virion-associated protein P3 from Caulimovirus (2O1J). (F) Long cylindrical containers. Fa, pentameric coiled 
coil, side and top views of the assembly domain of cartilage oligomeric matrix protein (1FBM); Fb, side and top views of 
the seven-helix coiled coil, engineered version of the GCN4 leucine zipper (2HY6). (G) Connectors. Ga, human heat shock 
factor binding protein 1 (3CI9); Gb, the bacterial cell division protein ZapA from Pseudomonas aeruginosa (1W2E). (H) 
Armature. Ha, side and top views of the envelope glycoprotein GP2 from Ebola virus (2EBO); Hb, side and top views of a 
complex between the N- and C-terminal peptides derived from the membrane fusion protein of the Visna (1JEK). (I) 
Tweezers or forceps. A complex between c-Jun, c-Fos and DNA. Proteins are shown as red helices, whereas DNA is shown 
as a blue cloud (1FOS). (J) Grabbers. Structure of the complex between βPIX coiled coil (red helices) and Shank PDZ (blue 
cloud) (3L4F). (K) Tentacles. Structure of the hexameric molecular chaperone prefoldin from the archaeum 
Methanobacterium thermoautotrophicum (1FXK). (L) Pullers. Structure of the ClpB chaperone from Thermus thermophilus 
(1QVR). (M) Chameleons. The C-terminal fragment of p53 gains different types of secondary structure in complexes with 
four different binding partners, cyclinA (1H26), sirtuin (1MA3), CBP bromo domain (1JSP), and s100ββ (1DT7). (N) 
Stackers or β-arcs. Na, stack of β-arches, β-amyloid; Nb, superpleated β-structure (Sup35p, Ure2P, α-synuclein); Nc, stack 
of β-solenoids (prion); Nd, stack of β-arch dimers (insulin); Ne, β-solenoids. Modified from Kajava et al. (2010)311. (O) 
Dynamic complexes. Schematic representation of the polyelectrostatic model of Sic1-Cdc4 interaction. Schematic 
representation of an IDP (ribbon) interacting with a folded receptor (grey shape) through several distinct binding motifs and 
an ensemble of conformations (indicated by four representations of the interaction). The intrinsically disordered protein 
possesses positive and negative charges (depicted as blue and red circles, respectively) giving rise to a net charge ql, while 
the binding site in the receptor (light blue) has a charge qr. The effective distance <r> is between the binding site and the 
center of mass of the intrinsically disordered protein. Reproduced from Mittag et al. (2010)203. 
 
Figure 13: Classification of disordered regions according to their evolutionary conservation (constrained, flexible 
and non-conserved disorder). (A) Schematic of computing disorder conservation and amino acid sequence conservation. 
The alignments are used to calculate the percentage of sequences in which a residue is disordered and the percentage of 
sequences in which the amino acid itself is conserved. A residue is considered to be conserved disordered if the property of 
disorder is conserved in at least half of species. Similarly, the amino acid type of a residue is considered conserved if it is 
present in at least half of species. Disordered residues in which both sequence and disorder are conserved are referred to as 
constrained disorder. Disordered residues in which disorder is conserved but not the amino acid sequence are referred to as 
flexible disorder. Residues which are disordered in S. cerevisiae but not cases of conserved disorder are referred to as non-
conserved disorder. (B) Disorder splits into three distinct phenomena. Functional enrichment maps of proteins enriched in 
flexible disorder versus constrained disorder. The area of each rectangle is proportional to the occurrence of that type of 
disorder in the alignments. Related gene ontology terms are grouped based on gene overlap. Adapted from Bellay et al. 
(2011)53. 
 
Figure 14: Repeat expansion creates IDRs. IDRs are abundant in repeating sequence elements, which suggest that repeat 
expansion is an important mechanism by which genetic material encoding for structural disorder is generated. The 
expanding repeats may fall into three classes (types) in terms of their functional diversification following expansion. 
Individual repeats may remain functionally equivalent (type I), or diversify (type II), or collectively acquire a completely 
new function (type III). Dark-tone red indicates structural disorder of the repeat, which may undergo full (dark-tone blue) or 
partial (green) induced folding upon binding to a partner. Adapted from Tompa (2003)60. 
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Figure 15: A summary of expression–function trends for human transcripts encoding highly disordered proteins. 
The x-axis represents the (log10) number of tissues in which the transcript is expressed; the y-axis represents the log10 
average magnitude of expression within the tissues. From the data, five distinct functional classes of highly disordered 
human proteins become apparent. 
 
Figure 16: Transcriptional and post-transcriptional gene regulation can be informative of IDR function. How 
inclusion of exons that code for IDRs is regulated during gene transcription and alternative splicing can give insights into 
the functional roles of the encoded disordered regions. For example, tissue- or developmental-specific regulation of 
alternative splicing or alternative promoter and polyadenylation site usage can be associated with important roles of the 
encoded IDRs in protein regulation and cellular interactions through for example the presence of binding motifs and 
phosphosites. Additionally, information on the conservation of patterns of exon inclusion (i.e. events shared among different 
evolutionary lineages versus species-specific events) can aid in better characterization of the encoded IDRs. The figure 
illustrates a hypothetical example where an exon (largest red box) that is included in a tissue-specific manner both in human 
and mouse encodes an IDR that embeds a phosphosite (P) and is involved in protein regulation. The human gene depicted in 
the figure has an additional exon (smallest red box), which encodes an IDR with a short interaction motif and which is also 
included in a tissue-specific manner in humans. Gene structures, mature mRNAs and corresponding protein isoforms are 
shown for human and mouse brain and heart tissues. On the right, possible functional roles of the IDRs encoded by the brain 
isoforms are illustrated. The examples illustrate how protein functional space can increase due to alternative splicing of 
exons that encode IDRs. 
 
Figure 17: Involvement of IDRs in phase transitions. (A) Interactions between proteins that contain multiple copies of a 
specific domain (an SH3 domain in the figure) and IDRs with multiple instances of its interaction motif (proline-rich SH3 
motif here) can, at appropriate concentrations, produce sharp liquid–liquid-demixing phase separations. This phase 
transition is likely to increase local ‘active’ protein concentrations exploitable for signaling switches. (B) High 
concentrations of low-complexity IDRs found in certain RNA binding domains lead to a reversible phase transition with the 
formation of highly dynamic hydrogels. These RNA granule-like assemblies consist of heteromeric protein aggregates and 
allow localization and storage of functionally related but non-identical RNA molecules. 
 
Figure Box 3: Disordered residues generally evolve more quickly than structured residues, but do display a wide 
range of evolutionary rates. Boxplots of the distributions of evolutionary rates for the predicted structured (blue) and 
disordered (red) residues across the human proteome. A residue with a high evolutionary rate is less conserved. 
Evolutionary rates were calculated using the rate4site algorithm309 on homolog alignments from 56 primarily vertebrate 
species.1 Disordered residues were predicted using MULTICOM-REFINE.308 Filled boxes represent the 50% of data points 
in the two quartiles above and below the median (which is represented by the horizontal bar within each box). Vertical lines 
(whiskers) connected to the boxes represent the highest and lowest non-outlier data points, with outliers being defined by a 
distance of more than 1.5 times the interquartile range from the median. Outliers are not shown for visual clarity. The 
distributions of evolutionary rates for disordered and structured residues differ significantly (P value < 10-15, Mann–
Whitney U test). 
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